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For most of its history, medicine has been considered an art. Medical practitioners’ personal 
experience and their culture’s prevailing belief systems dominated the way medicine was 
executed, spawning practices that were backed by little or no scientific evidence whatsoever. 
It is not possible to date the exact moment that medicine transgressed from being a healing 
art to a scientific discipline. In the Western European part of the world we can narrow it 
down to the nineteenth century, when empiricism relieved the practice of treating by 
anecdote and paved the way for what we consider modern medicine (Claridge and Fabian 
2005). Though clinical experience remains an invaluable accessory in delivering good patient 
care, evidence-based medicine (EBM) –clinical observations supplemented and explained by 
scientific data- constitutes the mainstay of medicine these days.  
However, despite the advances made in medical research over the past 150 years, we often 
still lack a comprehensive or even basic understanding of the mechanisms that govern our 
body in health and disease. As multi-morbidity and polypharmacy become the rule rather 
than the exception, a better understanding of pharmacodynamics (the effects a drug has on 
the body) and pharmacokinetics (the mechanisms by which the body processes and alters 
the drug) is necessary to avoid over- and underdosing the individual patient. Elucidating the 
correlations between clinically observed drug responses and specific quirks in our genetic 
makeup is the domain of a branch of pharmacology known as “pharmacogenetics”.  
Pharmacogenetics explores how genetic variations alter the function of those receptors, 
enzymes, transporters, and downstream signaling elements that ultimately affect drug 
response and metabolism. The term, coined by Friedrich Vogel in 1959, is often used 
interchangeably with the term “pharmacogenomics”, which cropped up much later in the 
1990s (Motulsky and Qi 2006). Strictly speaking, pharmacogenetics focuses on the 
exploration of single genes and their products, while pharmacogenomics takes a more 
holistic, i.e. genome-wide, approach. Budding in the 1950s, the field of pharmacogenetics only 
came into bloom at the turn of the millennium, when the advent of novel DNA sequencing 
methods accelerated genetic sequencing and capped its costs (Motulsky and Qi 2006). Since 
then, scanning patients for specific heritable genetic variants has become a viable option in 
clinical settings, adding a new dimension to the playing field of personalized medicine.  
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Generally, heritable genetic variants can affect gene products in two ways: the function of 
the gene product is either enhanced or impeded. The impact such altered functionality can 
have on metabolism is illustrated by the enzyme CYP2D6 of the cytochrome P450 family, 
which is involved in the metabolism of many opioids. Individuals with an impaired CYP2D6, 
so called “poor metabolizers” (PMs), are inefficient at metabolizing codeine into morphine. 
In consequence, they are exposed to codeine-related side effects without benefiting from 
morphine’s analgesic effects (Eckhardt et al. 1998). At the other extreme, people with rapid 
variants of CYP2D6 may metabolize codeine to morphine at such high rates that the 
accumulating morphine reaches undesirably high levels, with potentially lethal outcome 
(Ciszkowski et al. 2009; Crews et al. 2012).  
As DNA sequencing becomes faster and more readily accessible, pharmacogenetics can be 
an important tool in making personalized medicine more viable and efficient.  
1.2 Opioids 
1.2.1 General 
Opioids are a class of drugs defined by their ability to bind to endogenous opioid receptors. 
They are best known for their analgesic properties, though they are capable of eliciting a wide 
array of responses, depending on their chemical properties and their receptor affinities. The 
term “opioid” comprises the opiates, their metabolites, and semi-synthetic derivatives, as 
well as the newer classes of structurally unrelated synthetic opioids, and opioid receptor 
antagonists. Opioids should not be confused with endorphins, endogenous peptides 
synthesized in the brain and the original ligands for opioid receptors (Davis and Pasternak 
2009). Opiates morphine, codeine, and thebaine are plant alkaloids derived from Papaver 
somniferum, the opium poppy, and therefore considered “natural”, as opposed to those 
substances artificially designed to bind to opioid receptors such as fentanyl, sufentanil, or 
pethidine (Freye and Levy 2008). 
The analgesic properties of the juice won from the opium poppy have been exploited for 
thousands of years. The Ebers Papyrus, which dates back to 1500 BCE, documents the use 
of poppy seeds in sedative preparations, and the Sumerians are thought to have cultivated 
poppies as early as the third millennium BCE, supposedly to use them as euphoria-inducing 
stimulant in religious ceremonies- the Sumerian word for the poppy plant, “hul gil”, 
translates to “plant of joy” (Brownstein 1993; Freye and Levy 2008). Although an opium 
tincture called “laudanum” was frequently employed by chemists from the 16th century 
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onwards (with the first reports of abuse and addiction cropping up at about the same time), 
the active compound of opium was only isolated and described in 1806 by Friedrich 
Sertürner, who named it morphium (morphine) after one of the Ancient Greek gods of 
dreams, Morpheus (Brownstein 1993). First marketed in 1817 by Sertürner and Company, 
the commercial production of morphine began in 1827 (Wikipedia 2018b). Bayer made 
heroin (diacetylmorphine) commercially available in 1898, and in 1939 pethidine 
(meperidine) was discovered, making it the first synthetic opioid with a structure unrelated 
to that of morphine (Brownstein 1993). 
1.2.2 Pharmacodynamics 
An opioid’s effects depend on receptor affinity and intrinsic activity of the opioid, i.e. on 
how well it binds to a given receptor, and of what nature and magnitude the elicited response 
is, respectively.  
To date, four classes of opioid receptors have been identified. They are known as MOP (μ 
or mu), DOP (δ or delta), KOP (κ or kappa), and NOP (nociceptin or nociceptin/orphanin 
FQ peptide), in which “-OP” is shorthand for “opioid peptide receptor” (Freye and Levy 
2008; Dietis et al. 2011). Binding of an agonist to MOP is associated with analgesia, euphoria, 
respiratory depression, constipation, and itching, while KOP is thought to induce modest 
analgesia and feelings of dysphoria and displacement (Freye and Levy 2008; Dietis et al. 
2011). Opioids receptors –DOR and KOR in particular– are also emerging as targets in the 
treatment of mood disorders (Lutz and Kieffer 2013). All four opioid receptor classes are 7-
TM receptors that mediate their effects via G-class proteins, especially the Gi family, which 
inhibits the release of neurotransmitter from the presynaptic neuron in pain-transmitting 
fibers and thus accounts for much of the opioids’ analgesic effect (Freye and Levy 2008). 
A variety of MOP, DOP and KOP subtypes have been proposed. Originally, the existence 
of subtypes served to explain why the application of MOP agonists in combination with 
MOP antagonist selectively reversed some MOP-mediated effects while not affecting others 
(Dietis et al. 2011). The exploration of putative subtypes generated especial interest because 
it spurred hopes to tailor opioids that would bind to a receptor subset that induced analgesia 
but not to the ones implicated e.g. in respiratory depression (Dietis et al. 2011). However, 
knock-out experiments in mice yielded that the loss of the gene encoding for one opioid 
receptor caused the loss of all putative subtypes, leading to a reassessment of the traditional 
understanding of opioid receptor action (Dietis et al. 2011). Receptor heterodimerization, 
alternative splicing, and the interaction of downstream opioid receptor signaling pathways 
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with other signaling cascades have been proposed by more recent research to explain the 
observed differences in pharmacological responses (Corbett et al. 2006; Dietis et al. 2011). 
Apart from their receptor profiles, opioids also differ in how strongly they bind to the 
individual receptors, a property termed “affinity”. The stronger the affinity the opioids 
exhibit towards their respective receptors, the more potent is the response they elicit. 
Depending on their potency, opioids are roughly categorized as either weak or strong 
opioids. Codeine, dihydrocodeine, and tramadol are typical weak opioid analgesics, while 
morphine, oxycodone, levorphanol, methadone, hydromorphone, and fentanyl are 
considered strong opioids (WHO 1996; Brayfield 2014).  
Additionally, and irrespective of their receptor affinity, opioids can also be classified 
depending on the effect they have on a receptor, i.e. whether they elicit a response or inhibit 
it. Opioids act either as agonists (e.g. morphine, fentanyl), antagonists (e.g. naltrexone, 
naloxone), or mixed agonist-antagonist (e.g. buprenorphine, pentazocine).  
Due to their varied binding properties, opioids differ vastly in their pharmacological profile. 
While their ability to interact with opioid receptors classifies them as opioids, they do not 
bind to opioid receptors exclusively. The antitussive dextrorphan, for instance, binds little if 
at all to opioid receptors; it does, however, act as a NMDA-receptor antagonist. Morphine, 
the “classic” opioid, was shown to inhibit the release of the neurotransmitter acetylcholine 
and cause mast cell degranulation (Hermens et al. 1985; Davis 2009d). 
Subsequently, each opioid has to be assessed individually with regard to pharmacologic and 
pharmacokinetic parameters. 
1.2.3 Pharmacokinetics 
The pharmacological response ultimately depends not only on the opioid, but also on its 
pharmacokinetics. The pharmacokinetics of any given drug –and thus its impact on an 
organism– are influenced by four factors: absorption, distribution, metabolism, and 
elimination (ADME).  
Absorption of a drug depends on its chemical properties and the route of administration. 
While compounds such as fentanyl can be applied transdermally as patches, other opioids 
are best administered intravenously, either because they are absorbed poorly via the intestine 




Distribution describes the compartments (vasculature, cells, extracellular space) a drug can 
access and is especially relevant in the context of the brain-blood barrier. Many opioids exert 
their desirable –and undesirable– effects by acting upon the central nervous system. Access 
to the brain is limited by the blood-brain barrier, and only highly lipophilic compounds are 
thought capable of penetrating the barrier. Distribution is, therefore, a matter of a 
compound’s chemical properties. A highly lipophilic compound may diffuse into cells and 
accumulate in adipose tissue, whereas a highly polar substance will remain in the blood 
stream and be subjected to quick elimination through the kidneys. Thus, distribution affects 
half-life as much as the time and dose required to reach a steady state.  
Metabolism determines to what extent a given substance will be present in either activated 
or inactivated form. Most metabolic transformations –so called biotransformations– take 
place in the liver, where enzymes located within the hepatocytes prime xenobiotics for 
elimination by introducing modifications that render the drugs more hydrophilic. CYP2D6 
and CYP3A4 of the cytochrome P450 (CYP) family of enzymes are especially involved in 
opioid metabolism. For example, duplication of the CYP2D6 gene results in such accelerated 
metabolization of codeine that ultra-fast metabolizers have 50% higher plasma 
concentrations of morphine, a metabolite of codeine, than extensive metabolizers 
(Kirchheiner et al. 2007). 
Elimination, like distribution, has a major impact on a drug’s half-life. Since superfluous 
substances are excreted in bile and urine to a varying extent, especial care has to be taken in 
the application of drugs in patient suffering from liver or kidney disease. A number of 
commonly administered opioids, such as morphine, hydrocodone, or oxycodone, have 
higher bioavailability in patients with liver cirrhosis due to diminished metabolization. But 
while the effects of diminished CYP activity as well as that of other enzymes on opioid 
elimination and bioavailability have been extensively studied, the effects of diminished 
transporter activity have been less so. It is important to remember that non-membrane 
permeable substances rely on transporter proteins to shuttle them into the cell before they 
can be honed towards elimination. A study by Namisaki et al. showed that the expression of 
OCT1, among other transporters, was diminished in patients with hepatocellular carcinoma; 
however, chemotherapeutics employed in the treatment of this type of tumor depend on 
OCT1-mediated uptake into liver cells to reach their target (Namisaki et al. 2014). These 
findings indicate that not only phases 1 and 2, but also phases 0 and 3 of biotransformation 
–transporter-mediated uptake of drugs into cells and excretion from them, respectively– may 
be impaired in liver disease. 
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1.2.4 Effects of opioids and their role in clinical application 
Opioids are mainly employed for their analgesic properties, though weaker opioids are also 
used as antitussives and anti-diarrheal agents. Despite a wide range of available non-opioid 
analgesics, opioids continue to be the mainstay of perioperative pain treatment (Brayfield 
2014). Patients in chronic pain, such as cancer patients, also profit immensely from opioid 
therapy.  
The importance of opioids is also reflected in the rise in global opioid consumption. Between 
1989 and 2009 the consumption of morphine has risen sevenfold, that of oxycodone 26-
fold, and that of fentanyl 100-fold (International Narcotics Control Board  2011). This trend 
is mainly observed for countries with high gross domestic income, but as the fields of pain 
medicine and palliative care advance and more people in so-called developing countries gain 
better access to adequate treatment of (chronic) pain, it can be expected that the global 
consumption of opioids will continue to rise. 
Aside from the desired analgesic properties, opioids elicit a wide array of effects. Where 
opioids act upon the periphery, these effects take the shape of constipation, xerostomia (dry 
mouth), reduced libido, urinary retention, and pruritus (itching), while central nervous 
manifestations include sedation, respiratory depression, euphoria, dysphoria, and myoclonus.  
In general, opioids are consumed in two manners: either sporadically, such as in a 
perioperative setting, or chronically, such as in protracted pain states. It is important to 
distinguish these two groups, since opioid-native patients will react more sensitively to even 
small doses of opioid, while patients accustomed to opioids will require higher doses and be 
more resilient towards certain side effects (e.g. respiratory depression). 
When consumed on a regular basis, opioids cause gastrointestinal side effects. These side 
effects –often summarized as opioid-induced constipation, or opioid-induced bowel 
dysfunction (OIBD) – are the most pertinent to a patient’s immediate well-being since they 
cause the greatest discomfort (Leppert 2015). Laxatives, such as lactulose or senna, are first-
line therapies, but they can be supplemented with opioid receptor antagonists such as 
methylnaltrexone or alvimopan, both of whose effects are limited to the periphery since they 
cannot cross the brain-blood barrier (Davis 2009b). Nausea and vomiting are further 
common side effects when patients are started on opioids, but tolerance develops quickly, as 
it does in respiratory depression (Davis 2009b). Xerostomina (dry mouth) is caused by the 
anticholinergic effects of some opioids, especially morphine. 
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The most dreaded side effect of opioid therapy is respiratory depression. Depression of the 
respiratory center is dose-dependent, which is why opioids with high potency, such as 
sufentanil, are only titrated under closely monitored conditions, e.g. during general 
anesthesia. Accidental opioid overdosing that leads to respiratory depression can also happen 
when the opioid in question is insufficiently cleared from the bloodstream, such as in acute 
kidney injury (Conway et al. 2006). Although nociceptive stimuli counteract respiratory 
depression by increasing respiratory rate, respiratory depression continues to be a serious 
problem in patients who are either very old or very young, opioid-naïve, or already suffering 
from respiratory impairment (Davis 2009b). In this context, knowledge of genetic variations 
in the metabolic pathway of opioids can be helpful in averting a potentially life-threatening 
accumulation of opioids. 
Addiction is another major adverse effect to bear in mind when administering opioids. The 
term “addiction” describes a chronic disease with a strong psychological component and 
detrimental socioeconomic consequences for affected individuals (in contrast to “tolerance” 
and “dependence”, which describe physical adaptation to drug consumption) (ASAM 2001; 
Rosenblum et al. 2008). In 2013, 37% of the 44,000 drug-related deaths in the US were 
attributed to prescription opioids, an additional 19% to heroin (Volkow and McLellan 2016). 
While substance abuse in cancer patients under chronic opioid medication with no prior 
history of drug abuse is rare, and addiction is not known to develop in patients who receive 
opioids for a short time as part of their peri-operative analgesic treatment, the prevalence of 
opioid addiction and dependence among patients on (recklessly prescribed) long-term opioid 
therapy is high (Kirsh et al. 2009; Volkow and McLellan 2016). 
1.2.5 Role of OCT1 in opioid metabolism 
All the effects mentioned above –the desirable as well as the undesirable– depend on the 
bioavailability of opioids. Pharmacists and physicians have begun to recognize that 
bioavailability is influenced not only by route of application and co-medication, but also by 
genetics. The ideal dose of medication may differ significantly between individuals, or even 
within an individual, depending on whether they receive additional medication or 
supplements that interfere with signaling cascades and drug metabolism. 
Since the vast majority of opioids are weak bases, which are protonated and carry a charge 
at physiological pH, the OCT family of organic cation transporters have come to attention 
as likely mediators of phase 0 biotransformation in opioid metabolism. For instance, 
Tzvetkov et al. demonstrated that the uptake of morphine is affected by polymorphisms in 
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the OCT1 gene. Loss-of-function phenotypes resulted in elevated plasma concentrations of 
morphine in affected patients, which improved analgesia but also increased the risk of 
accidental overdosing (Fukuda et al. 2013; Tzvetkov et al. 2013). 
Another opioid whose plasma concentration is elevated in the presence of loss-of-function 
OCT1 genotypes is O-desmethyltramadol, the active metabolite of tramadol (Tzvetkov et al. 
2011). The effect is so marked that, in a clinical study, patients with either one or two loss-
of-function OCT1 alleles consumed less tramadol after surgery than patients with two wild 
types OCT1 alleles (Stamer et al. 2016). 
Thus, OCT1 has been shown to affect plasma concentrations of both a classic and a synthetic 
opioid to a clinically significant degree. 
1.3 Human organic cation transporter 1 (OCT1) 
Everything we ingest –food, fluid, pharmaceuticals– has to be transported across the barrier 
of the gastrointestinal tract into our bloodstream. Even when administered intravenously or 
epidurally, many compounds will only be effective once they arrive inside our cells. 
These transitions –from outside the body to within, and from extracellular to intracellular– 
are mediated by two mechanisms: diffusion and transport. While for a long time drug-
metabolizing enzymes were the sole focus of pharmacogenomic research, attention has 
shifted over the past decade to membrane transporters (Yee et al. 2010). The role of 
membrane transporters on tissue and plasma concentrations of certain drugs is now widely 
recognized, and current and future research is expected to provide a better understanding of 
interactions between membrane transporters, drug-metabolizing enzymes, and their genes 
(Giacomini et al. 2010; Yee et al. 2010). The human organic cation transporter 1 (OCT1) is 
only one of the transporter in the spotlight of current research.  
1.3.1 OCT1 gene (SLC22A1) 
The human organic cation transporter 1 (OCT1, occasionally hOCT1 to better distinguish it 
from rat and mouse Oct1) is a transporter primarily expressed in the sinusoidal membranes 
of the liver, where it facilitates diffusion of polyspecific cations from the bloodstream into 
the liver cells (Grundemann et al. 1994; Zhang et al. 1997). It is a member of the solute 
carrier family of transport proteins, which belong to the major facilitator superfamily 
(Koepsell 2011; Pelis and Wright 2014). The gene encoding for OCT1, SLC22A1, is located 
on the long arm of chromosome 6 (6q25.3), and its corresponding mRNA comprises an 
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open reading frame of 1662bp, encoding a protein 554 amino acids in length (Gene: 
SLC22A1  ; Zhang et al. 1997). Apart from in the liver, OCT1 is weakly expressed in the 
kidneys and intestine, and OCT1 mRNA has been detected in the adrenal gland and lung 
(Nies et al. 2009; Tzvetkov et al. 2009). There is also some evidence that OCT1 expressed in 
the endothelial cells of brain vessels mediates the passage of drugs across the blood-brain 
barrier (Dickens et al. 2012).  
1.3.2 Structure of OCT1 
OCT1 is believed to be made up of twelve transmembrane helices (TMH) connected by 
intracellular and extracellular loops (Grundemann et al. 1994; Zhang et al. 1997; Keller et al. 
2011). As the crystal structure of OCT1 has yet to be obtained, considerations as to OCT1’s 
structure rely mostly on models fashioned after LacY (lactose permease), a bacterial 
transporter that also belongs to the major facilitator superfamily (Pelis and Wright 2014). 
Site-directed mutagenesis is another tool that has helped to elucidate the structure of the 
binding regions (Popp et al. 2005; Gorbunov et al. 2008). According to these models, OCT1 
contains two large loops: one located between TMH 1 and 2 on the extracellular side, and 
one between TMH 6 and 7 on the intracellular side (Keller et al. 2011). The extracellular loop 
does not directly participate in substrate translocation, but mutations within the loop of 
rOct1 lead to a decrease in plasma membrane translocation of rOct1 (Keller et al. 2011). This 
observation is supported by findings from Seitz et al, who showed that six polymorphisms 
of OCT1, two of which were located in the extracellular loop, led to a retention of transporter 
within the endoplasmic reticulum (Seitz et al. 2015). The intracellular loop contains four 
potential phosphorylation sites; a fifth is at the C-terminal domain, which, like the N-
terminus, is located on the intracellular side (Zhang et al. 1997). A study by Ciarimboli et al 
proposes that OCT1 activity is inhibited by PKA-mediated phosphorylation and stimulated 
by Ca2+/Calmodulin, Ca2+/Calmodulin-dependent CamKII, and p56lck tyrosine kinase 
(Ciarimboli et al. 2004). 
Binding of a substrate to OCT1 induces a conformational change that displaces the bound 
substrate from extracellular to intracellular (or vice versa). rOct1 has three putative binding 
sites: one with a high, the other two with a low substrate affinity (Koepsell 2011). It has been 
hypothesized that substrate binding to the high affinity site may allosterically impact the low 
affinity sites and alter their transport capacities (Gorbunov et al. 2008). The proposed 
mechanism is one of many that would explain why some molecules act as inhibitors of OCT1 
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without being transported, and why IC50 values vary depending on the concentration of the 
inhibited agent (Gorbunov et al. 2008). 
In order to shuttle a substrate from one side of the cell to the other, be it by passive or active 
transport, the transport protein has to undergo a number of conformational changes: open 
outward-facing, occluded, and open inward-facing (Gouaux 2009). This model applies to 
OCT1, where conformational changes are induced by substrate binding, in contrast e.g. to 
voltage-gated Na-channels, where conformation is determined by membrane potential 
(Egenberger et al. 2012). Due to its penchant for (positively) charged molecules, the transport 
processes mediated by OCT1 are electrogenic, and it has been proposed that membrane 
potential influences the equilibrium between the open outward-facing and the open inward-
facing conformation (Busch et al. 1996b; Koepsell 2011).  
1.3.3 Substrates and inhibitors of OCT1 
To date, a number of compounds with diverse chemical structures have been identified as 
substrates of OCT1 (see Figure 1), among them morphine, O-desmethyltramadol, 
odansetron, sumatriptan, amisulpride, tiatropium, and amiloride (Tzvetkov et al. 2011; 
Tzvetkov et al. 2012; Hendrickx et al. 2013; Matthaei et al. 2016; Chen et al. 2017). Putative 
endogenous substrates include monoamines, such as the neurotransmitters serotonin, 
norepinephrine, dopamine, acetylcholine, and histamine, as well as thiamine (vitamin B1) 
(Busch et al. 1996a; Boxberger et al. 2014; Chen et al. 2014). MPP+ (1-methyl-4-
phenylpyridinium), TEA (tetraethylammonium), and ASP+ (4-(4-(dimethylamino)styryl)-N-
methylpyridinium iodide) are established model substrates for OCT1 in research (Busch et 





Figure 1: Chemical structures of selected substrates of OCT1 
Despite their diversity, the substances intersect in at least four respects, as demonstrated by 
the example of morphine (see Figure 2). The first is charge. Although OCT1 does not 
exclusively transport molecules that are positively charged, most of its substrates do have a 
basic nature. The second is that they contain nitrogen, which may be quaternary at 
physiological pH; methylation can further stabilize the resulting positive charge at the 
nitrogen atom (as in N-methylated tilidine and unmethylated nortilidine). A third property is 
a cyclic structure or aromatic ring, which is integral to the substrate’s structure. Finally, OCT1 
substrates tend to exhibit low lipophilicity. Low lipophilicity in a compound, e.g. in the form 
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of hydroxyl groups, increase the likelihood that it cannot diffuse through cell membranes, 
thus having to rely on transporter proteins to ferry it across. However, data suggest that a 
certain degree of lipophilicity is necessary to enable substrate-transporter interaction, which 
is enhanced in the absence of hydrogen-bond donors (Ahlin et al. 2008). In addition, a study 
by Hendrickx et al. concluded that molecular volume was an important characteristic of 
OCT1 substrates, with increased volumes diminishing the likelihood that a given substances 
is a substrate of OCT1 (Hendrickx et al. 2013).  
 
Figure 2: Chemical structure of morphine.  
Morphine illustrates some of the features typical of an OCT1 substrate: a methylated 
nitrogen atom, which, at physiological pH, will carry a positive charge; five cyclic rings that 
enhance lipophilicity, one of which is aromatic; and two polar hydroxyl groups. 
On the other hand, various compounds inhibit OCT1 without being transported by it. Ahlin 
et al. concluded that the four most important features for an OCT1 inhibitor are 
hydrophobicity, lipophilicity, positive charge, and an absence of hydrogen –bonding moieties 
(Ahlin et al. 2008). While it is not entirely possible to predict what substance will act upon 
OCT1 as substrate or inhibitor –or at all– there is some evidence that lipophilic substances 
tend to be inhibitors rather than substrates (Ahlin et al. 2008). 
1.3.4 Genetic variability of OCT1 
The OCT1 gene is highly genetically polymorphic. Seitz et al. reported 85 variants within 
the 2770bp long SLC22A1 gene locus; of those, 44 lay within the coding region, and 29 
caused amino acid substitutions (Seitz et al. 2015). OCT1 polymorphisms leading to 
incorrect compartmentalization of the transporter resulted in a global loss of activity, 
indiscriminate of substrate, whereas loss-of-function variants inserted into the plasma 
membrane displayed substrate specific loss-of-function (Seitz et al. 2015).  
Loss-of-function OCT1 polymorphisms in the general population vary globally among 
regions and ethnic groups. While the frequency of reduced or loss-of-function alleles is 
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below 2% in Chinese and Japanese populations, 40% of Caucasians carry one allele and 9% 
carry two alleles with the most common loss-of-function polymorphisms (Chen et al. 2010; 
Seitz et al. 2015). 
1.3.5 OCT1 and pharmacogenetics research 
Given the plethora of transporters so far identified (more than 15,000 transport protein 
sequences in over 1,200 families as of December 2017 (Transporter Classification 
Database)), what distinguishes OCT1 and makes it an especially interesting target for medical 
research?  
First of all, OCT1 is mainly located in the sinusoidal membrane of hepatocytes (Gorboulev 
et al. 1997; Zhang et al. 1997). The liver is the body’s powerhouse of metabolism; 
detoxification and elimination of both endogenous and exogenous compounds occur 
primarily here. This process, dubbed biotransformation, ultimately leads to the deactivation 
and elimination of xenobiotics. As gatekeeper to the intracellular metabolic machinery of the 
hepatocytes, OCT1 is part of phase 0 biotransformation. However, in some cases, instead of 
rendering xenobiotics ineffective, CYP-mediated modifications can also lead to their 
activation, as is the case with prodrugs tilidine and codeine, whose metabolites nortilidine 
and morphine, respectively, elicit the clinical effects associated with their parent compounds. 
Occasionally, activation also results in toxification, as with pethidine or acetaminophen, 
causing a potentially harmful accumulation of toxic metabolites in vulnerable patient groups, 
such as patients suffering from impaired renal clearance (Ramirez et al. 2004; Laine et al. 
2009). Slightly overstated, it can be said that transport of many drugs into the liver cells, 
where they are deactivated (their effects on the body thus being terminated) or activated 
(thus becoming effective) would be diminished without OCT1.  
Secondly, OCT1’s high genetic variability has been shown to impact OCT1’s transport 
capacities to a degree that is clinically significant. Diminished uptake in loss-of-function 
OCT1 polymorphisms has been shown for morphine, tramadol, and sumatriptan, effectively 
causing an increase in their bioavailability and half-life (Tzvetkov et al. 2012; Tzvetkov et al. 
2013; Matthaei et al. 2016). Considering that a great number of drugs fulfill the formal criteria 
for OCT1 substrates and inhibitors, it would be of both use and interest for clinicians to 
know which drugs interact with OCT1, and whether their pharmacokinetic properties are 
altered in other-than wild type OCT1 variants.  
Thirdly, the current list of substrates and inhibitors of OCT1 comprises substances that are 
staple drugs in clinical practice. Xenobiotics transported by OCT1 include morphine, O-
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desmethyltramadol, odansetron, tropisertron, and sumatriptan, to name only a few 
(Tzvetkov et al. 2011; Tzvetkov et al. 2012). Endogenous substrates of OCT1, on the other 
hand, remain elusive; so far only monoamines and vitamin B1 have been identified (Busch 
et al. 1996a; Chen et al. 2014). It seems, therefore, as if OCT1’s primary role is to shuttle 
exogenous substrates into the liver for deactivation and detoxification.  
For these reasons, OCT1 is a variable in drug metabolism worthy of attention. Knowing 
which opioids are impacted by OCT1 polymorphisms –and which opioids in turn impact its 
transport capacities– could help clinicians make better informed choices concerning the 
administration of opioids, their dosage, and co-medication.  
1.4 Aim 
The aim of this work was to perform a systematic screening of opioids in order to identify 
substrates and inhibitors of OCT1 beyond the previously identified morphine and O-
desmethyltramadol. Screening for individual compounds as substrates and inhibitors of 
OCT1 was performed in four steps:  
- in silicio predictions of the compounds’ basic properties and lipophilicity  
- experimental determination of their passive membrane permeability using parallel artificial 
membrane permeability assays (PAMPAs) 
- determination of their inhibitory potential on OCT1 
- determination of their uptake by OCT1 
The in silicio predictions helped us in the initial selection process by identifying opioids with 
low or even negative logD(7.4) values, which indicate limited lipophilicity. The premise was 
that substances with low membrane permeability are more likely to require transporters to 
penetrate biological membranes than lipophilic substances. The PAMPAs that followed 
experimentally validated the substances’ membrane permeability in an artificial, well-defined 
but cell-free model. The degree to which substances did or did not interact with OCT1 was 
evaluated with the help of the inhibition experiments, while the direct transport 
measurements identified those substances that interacted with OCT1 as substrates (as 
opposed to mere inhibitors).  
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ASP+ Invitrogen, Darmstadt, Germany 
Bicinchoninic Acid Solution Sigma-Aldrich, Steinheim, Germany 
Copper sulfate solution Sigma-Aldrich, Steinheim, Germany 
EDTA 0.5 M solution AppliChem, Darmstadt, Germany 
Fecal Calf Serum (FCS) Gibco Life Technologies, Darmstadt, Germany 
Formic acid Merck-Schuchard, Hohenbrunn, Germany 
HBSS+ Gibco Life Technologies, Darmstadt, Germany 
Helipur® H plus N B.Braun Medical AG, Sempach, Switzerland 
Medium Gibco Life Technologies, Darmstadt, Germany 
Methanol LCMS grade LCG Standards GmbH, Wesel, Germany 
MPP+ Sigma-Aldrich, Steinheim, Germany 
NaCl Merck, Darmstadt, Germany 
Na-deoxycholate Sigma-Aldrich, Steinheim, Germany 
Nonidet®P40 Substitute 
(Nonylphenylethylenglycol) Fluka (Sigma), Germany 
PBS buffer AppliChem, Darmstadt, Germany 
Penicillin and Streptomycin (P/S) Gibco Life Technologies, Darmstadt, Germany 
Poly-D-lysine bromide Sigma-Aldrich, Steinheim, Germany 
PromoChem Acetonitrile Optigrade LCG Standards GmbH, Wesel, Germany 
Sodium dodecyl sulfate (SDS) BioRad, Hercules, USA 
Tris-HCl Roth, Karlsruhe, Germany 
TrypLE Gibco Life Technologies, Darmstadt, Germany 
Tryptane Blue Sigma-Aldrich, Steinheim, Germany 
Water LCMS grade  LCG Standards GmbH, Wesel, Germany 
2.1.2 Drugs 
Drugs Manufacturer 
3-Methoxymorphinan hydrochloride Sigma-Aldrich, Steinheim, Germany 
3-Hydroxymorphinan hydrobromide Sigma-Aldrich, Steinheim, Germany 
Codeine Sigma-Aldrich, Steinheim, Germany 
Dextromethorphan solution Sigma-Aldrich, Steinheim, Germany 
Dextrorphan tartrate Sigma-Aldrich, Steinheim, Germany 
Fentanyl solution Sigma-Aldrich, Steinheim, Germany 
Hydrocodone bitartrate Sigma-Aldrich, Steinheim, Germany 
Hydromorphone Sigma-Aldrich, Steinheim, Germany 
Meptazinol hydrochloride Sigma-Aldrich, Steinheim, Germany 
Methylnaltrexone bromide Sigma-Aldrich, Steinheim, Germany 
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Morphine Sigma-Aldrich, Steinheim, Germany 
Naltrexone solution Sigma-Aldrich, Steinheim, Germany 
N-Desmethyl-cis-tramadol 
hydrochloride solution Sigma-Aldrich, Steinheim, Germany 
Norfentanyl oxalate solution Sigma-Aldrich, Steinheim, Germany 
Noroxycodone hydrochloride solution Sigma-Aldrich, Steinheim, Germany 
Nortilidine hydrochloride solution Sigma-Aldrich, Steinheim, Germany 
Oxycodone Sigma-Aldrich, Steinheim, Germany 
Oxymorphone (solution) Sigma-Aldrich, Steinheim, Germany 
Pethidine (Meperidine) hydrochloride Sigma-Aldrich, Steinheim, Germany 
Piritramide Janssen-Cilag GmbH, Neuss, Germany  
Sufentanil citrate LGS Standards, Wesel, Germany 
Tapentadol Sigma-Aldrich, Steinheim, Germany 
Tilidine hydrochloride Sigma-Aldrich, Steinheim, Germany 
 
2.1.3 Cell lines 
Cell lines Generated by 
HEK 293 hOCT1 Ali Reeza Saadatmand 
HEK 293 pcDNA5 Ali Reeza Saadatmand 
2.1.4 Consumables 
Equipment Manufacturer 
96-well plate, clear Sigma-Aldrich, Nümbrecht, Germany 
96-well PCR plate Thermo Scientific, Loughborough, UK 
Adhesive Sealing Sheets Thermo Fisher Scientific, Darmstadt, Germany 
Cakes and cookies Tina, Marleen, Mladen, Karo, Ellen, Helen, Jiayin 
Cell culture flasks, 75 cm2  Sarstedt, Nümbrecht, Germany 
Centrifuge tubes, 15 ml Sarstedt, Nümbrecht, Germany 
Centrifuge tubes, 50 ml Sarstedt, Nümbrecht, Germany 
Discardit II™ 20 ml syringe BD Biosciences, Heidelberg, Germany 
Disposable gloves 
Rösner-Mautby Meditrade Holding GmbH, Kiefersfelden, 
Germany 
Flat cap strips, 8 Thermo Fisher Scientific, Darmstadt, Germany 
Ethanol 99 % (methylated), diluted 
with ddH2O to 70 % Walter CMP GmbH, Ratingen, Germany 
Filtered tips, 200 µl Kisker, Steinfurt, Germany 
Glass pasteur pipet, 230 mM Brand, Wertheim, Germany 
Glass Vial Micro-Insert 0.05 ml Th. Geyer, Renningen, Germany 
Minisart® plus Syringe Filters  Sartorius, Göttingen, Germany 
Narrow tips, 100 µl Sarstedt, Nümbrecht, Germany 
NunclonTM Delta Surface, 12-well 
plates ThermoScientific, Roskilde, Denmark 
Parafilm® Brand, Wertheim, Germany 
Pre-coated PAMPA Plate System Corning, Bedford, MA, USA 
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Septum 8 mM PTFE virginal VWR International GmbH, Darmstadt, Germany 
Serological  pipet, 5 ml Sarstedt, Nümbrecht, Germany 
Serological pipet, 10 ml Sarstedt, Nümbrecht, Germany 
Serological pipet, 25 ml Sarstedt, Nümbrecht, Germany 
Test tubes, 1.5 ml Sarstedt, Nümbrecht, Germany 
Test tubes, 2.0 ml Sarstedt, Nümbrecht, Germany 
Test tubes, 5.0 ml Sarstedt, Nümbrecht, Germany 
Tips, 10  µl Sarstedt, Nümbrecht, Germany 
Tips, 1000 µl Sarstedt, Nümbrecht, Germany 
Tips, 200 µl Sarstedt, Nümbrecht, Germany 
2.1.5 Reusable equipment 
Equipment Manufacturer 
96-well plate, black with clear bottom Corning Incorporated, Corning, USA 
Cover slip Schütt, Göttingen, Germany 
Neubauer Cell Counting Chamber Schütt, Göttingen, Germany 
Screw neck vials for autosampler VWR International GmbH, Darmstadt, Germany 
Screw tops without septa for vials VWR International GmbH, Darmstadt, Germany 
Spring for Micro Insert 0.05 ml VWR International GmbH, Darmstadt, Germany 
2.1.6 Instruments 
Instruments Manufacturer 
Analytical balance Sartorius, Göttingen, Germany 
API4000 LC-MS/MS system AB Sciex, Darmstadt, Germany 
Arium® pro VF Ultrapure Water 
System Sartorius, Göttingen, Germany 
Axiovert 40 CFL microscope Carl Zeiss Microscopy GmbH, Göttingen, Germany 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
CO2Incubator BBD 6220   ThermoFischer Scientific, Osterode, Germany 
Ecovac safety vacuum system Schuett-biotec GmbH, Göttingen, Germany 
Fridges and freezers Liebherr, Biberach an der Riß, Germany 
Heraeus Biofuge Pico ThermoFischer Scientific, Osterode, Germany 
Heraeus Multifuge X3R ThermoFischer Scientific, Osterode, Germany 
Magnetic stirrer 2mag, Munich, Germany 
MS2 Minishaker W.Krannich GmbH, Göttingen, Germany 
Polymax 1040 Platform Shaker Heidolph Instruments GmbH, Schwabach, Germany 
Sample Concentrator Techne, Stone, UK 
Stretching Table OTS40, 150 x 400 x 
80 mm (W/D/H) Medite, Burgdorf, Germany 
Tecan Ultra microplate reader Tecan, Crailsheim, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 





ADMET Predictor Simulations Plus Inc., Lancaster, USA 
Analyst® Version 1.4.2 Applied Biosystems, Darmstadt, Germany 
ChemBioDraw Ultra 14.0.0.117 PerkinElmer Inc. 
EndNote X7.3.1 Thomson Reuters, Philadelphia PA, USA 
GIMP Image Editor 2.8 (GNU 
Image Manipulation Program) 
Spencer Kimball, Peter Mattis and the GIMP 
Development Team 
GraphPad Prism 5 GraphPad Software Inc. 
Microsoft Excel 2013 Microsoft Corporation, Redmond, WA, USA 
Microsoft Word 2013 Microsoft Corporation, Redmond, WA, USA 
SigmaPlot 12.0 Systat Software Inc., Erkrath, Germany 




2.2 Methods  
2.2.1 Cell culture 
The cells were kept in 75 cm2 cell culture flasks with Dulbecco’s Modified Eagle Medium 
(DMEM), which was supplemented with 10 % fecal calf serum (FCS) and 1 % 
penicillin/streptomycin mix (P/S) (hereafter referred to as “medium”). The flasks were 
cultivated in an incubator at 37 °C and 5% CO2. Depending on cell growth and plating 
frequency, the cells were split every 2-5 days. Passages between 4 and 31 were used for 
plating. 
2.2.2 Plating 
The cells were grown on 12-well plates. To enhance cell adhesion, the wells were coated with 
poly-D-lysine by adding 0.5 µl of poly-D-lysine solution to each well and incubating the plate 
in a cell culture incubator at 37 °C for 15 min. The superfluous poly-D-lysine was then 
removed from the wells and stored at 4 °C for reuse. 
Poly-D-lysine solution was prepared by mixing 100 mg of D-lysine with 50 ml of ddH2O. 
This solution was filtered through a syringe with a filter tip before use. 
For plating, the medium was removed from the cell culture flask and 3.5 ml of trypsine added 
to the flask. The flask was then incubated in the cell culture incubator at 37 °C for 4 min. 
during which time the trypsine dissolved the extracellular matrix that bonded the cells 
together into a biofilm. As soon as the time was up, the flask was removed from the incubator 
and 10 ml of medium were added to terminate the trypsine reaction. The cells were then 
ablated from the bottom of the flask, transferred into a falcon tube, and the tube centrifuged 
for 3min. at 700 x g. The medium was then removed from the tube and the cell pellet at the 
bottom of the tube resuspended in 10 ml of fresh medium. Of this cell suspension, 20 µl was 
added to a test tube and mixed with 20 µl of trypthane blue. A sample of the dyed cell 
solution was pipetted onto a cell counting chamber and the cells counted under a light 
microscope. The sum of the cells from the four fields of the counting chamber was divided 
by two and multiplied with 104 to yield the total number of cells per milliliter. The cell 
solution was then diluted with medium to meet the concentration of cells required, i.e. 6x105 
cells per well. Of this final cell solution, 1ml was added to each well. 
For the inhibition experiments, three wells of a 12-well plate were plated with pcDNA5 cells 
and nine wells with OCT1-overexpressing cells. For the transport experiment four wells of 
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a 12-well plate were plated with pcDNA5 cells and eight wells with OCT1-overexpressing 
cells. 
2.2.3 In silicio predictions 
Initially, we compiled a list of 60 opioids and opioid congeners by reviewing pharmacological 
and medical textbooks, and by browsing PubMed and Wikipedia. Especially those opioids 
and their congeners were considered of interest that are either well established in clinical 
practice and widely used, or else belong to newer, emerging classes of opioids, whose 
pharmacological interactions have yet to be elucidated. 
On the basis of the substances’ chemical structure, which were obtained from PubChem 
(The PubChem Project), three values were predicted with ADMET Predictor Software: the 
dissociation constant pKa; the partition coefficient logP (the log of the ratio of unionized 
compounds in a lipophilic and a hydrophilic phase); and the distribution coefficient logD(7.4) 
(log of the ration of the sum of both unionized and ionized compound in a lipophilic and a 
hydrophilic phase). The logD(7.4) values were of greatest interest to us as they best reflect 
lipophilicity under physiological conditions, which were also the conditions emulated in the 
inhibition and transport experiments.  
2.2.4 Parallel artificial membrane permeability assays (PAMPAs) 
Drug solutions of the 23 substances selected to undergo this experiment were prepared at 
three different concentrations each. They were prepared in phosphate buffered solution 
(PBS) to yield aliquots of 400 µl with concentrations of 20 µM, 100 µM, and 500 µM, except 
for codeine, fentanyl, and morphine, which were prepared at 10 µM, 20 µM, and 50 µM.  
Of these drug solutions, 300 µl was added to the donor wells (lower plate) of the PAMPA 
plate. The remaining 100 µl was set aside as C0 samples and their exact concentration 
determined via mass spectrography (MS) in order to adjust for inaccuracies that might have 
occurred during pipetting.  
Once the donor wells had been prepared, 200 µl of PBS was added to each well of the 
acceptor wells (upper plate). The upper plate was then carefully placed into the lower, 
trapping as little air between the membranes as possible, since bubbles impede diffusion 
between the two plates. The PAMPA plates were then set aside at room temperature (21ºC) 
and not disturbed for 5 h.  
After incubating for 5 h, the PAMPA plates were separated and the lower plate set aside. 
Starting with the acceptor plate, 180 µl of solution from each well was transferred into a 
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corresponding well on a standard 96-well PCR plate. Analogously, 180 µl of solution from 
the donor wells was transferred into corresponding wells on a second standard 96-well PCR 
plate. The samples from the acceptor plate were designated C5A (concentration after 5 h, 
acceptor plate), those of the donor plate C5D (concentration after 5 h, donor plate). 
Before MS measurements, the samples from C0 and C5D were diluted 1:10,000 in 0.1 % 
formic acid. The samples from C5A were initially measured undiluted, but as their 
concentrations exceeded the detection capacities of the mass spectrometer, the samples were 
likewise diluted in 0.1% formic acid, either 1:100 or 1:10,000 depending on how strong the 
initial signal detected by the mass spectrometer was. The different dilution ratios were later 
taken into account when the results of the MS measurements for C0, C5A, and C5D were 
converted into mM (millimolar) for calculation. 
Permeability and mass retention were calculated according to the formula provided by the 
producer of the PAMPA plates.  
Recommended formula for data analysis provided by the producer 
 
C0   = initial compound concentration in donor well in [mM] 
CD(t)   = compound concentration in donor well at time t in [mM] 
CA(t)    = compound concentration in acceptor well at time t in [mM] 
VD    = donor well volume 
VA    = acceptor well volume 




A   = filter area (0.3 cm2) 
t   = incubation time in s (5 h= 18,000 s) 
2.2.5 Inhibition experiments 
The IC50s of the substrates were determined with 4-(4-(dimethylamino)styryl)-N-
methylpyridinium iodine (ASP+). A fluorescent molecule that can be easily quantified by 
photometer measurements, ASP+ is also an established substrate of OCT1. As such, its 
uptake depends on OCT1's transport capacities, which will be diminished in the presence of 
an inhibitor or that of a competing substrate. The competing substances (hereafter referred 
to as “test drug”) were the 23 opioids selected for testing.  
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ASP+ uptake was measured at eight different concentrations of test drug, including a 
concentration of zero, which served as the baseline of ASP+ uptake by OCT1 and pcDNA5 
cells. Drug concentrations of 1, 5, 10, 50, 100, 500, and 1000 µl were obtained through serial 
dilution of a stock solution with high molar mass. Oxycodone was measured at higher 
concentrations of 0, 10, 50, 100, 500, 1000, 2000, 5000 µl after initial measurements at lower 
concentrations yielded inconclusive results. All samples were diluted with Hank’s Balanced 
Salt Solution (HBSS+) and prepared at twice the target concentration, so that when the test 
drug solution was mixed with an equal amount of ASP+ solution shortly before the 
experiment the final solution yielded the concentrations desired for testing. 
ASP+ solution was prepared from a 10 mM stock solution with HBSS+ as diluent. As with 
the inhibitor solutions, the solution was prepared at a concentration of 1 µM and the target 
concentration of 0.5 µM obtained when equal volumes of 1 µM ASP+ and test drug solution 
were mixed prior to the experiment.  
The uptake measurements were performed under (human) physiological conditions. These 
conditions were met by adjusting the HBSS+ buffer to fall within a pH range of 7.3- 7.5 and 
by warming it up to 37 °C in a water bath prior to the experiments. Eppendorf tubes 
containing the ASP+-test drug solutions were also kept on a heating block at 37 °C until the 
solutions were added to the cells.  
The cells were prepared for the experiment by discarding the old medium within the wells 
and washing them once with 2ml of pre-warmed HBSS+ per well. This, too, was completely 
removed.  
The experiment began with the addition of the ASP+-test drug solution to the wells. 400 µl 
of ASP+-test drug solutions were added to the OCT1-containing wells, with ASP+ at a 
concentration of 0.5 µM and test drug at the aforementioned concentrations. Additionally, 
pure 0.5 µM ASP+ solution without test drug was added to two of the OCT1 wells and both 




Figure 3: Plating and pipetting scheme for inhibition experiments, concentrations in µM 
The plates were kept at 37 °C on a hot plate during the entire course of the experiment to 
allow for optimal uptake of ASP+ and test drug under physiological conditions. After an 
incubation period of 2 min, the reaction was stopped by adding 2 ml of ice-cold HBSS+ to 
each well. This was discarded, and the cells were washed two more times with ice-cold 
HBSS+.  
The cell lysate required for fluorescence measurement was won by removing all vestiges of 
HBSS+ buffer and lysing the cells with 0.5 µl of RIPA buffer per well.  
 
RIPA buffer 




NaCl 150 mM 
EDTA 1 mM 
 
The plates were then placed on the Shaker for 10 min. to ensure complete lysis had taken 
place, followed by 10 min. of centrifugation at 700 x g. Centrifugation was not mandatory, 
but performed nonetheless because it helped to isolate the DNA and thereby facilitated 
pipetting. Cell lysate from each well, 200 µl and 10 µl, were transferred to a 96-well black 
bottom for fluorescence measurements and to a standard 96-well plate for protein 
measurements, respectively. A standard of bovine serum albumin (BSA) of 0, 1, 3, 5, 10, and 
15 µl was added in duplicate to the standard 96-well plate. 200 µl of a bicinchoninic acid 
mastermix prepared from 200 µl of bicinchoninic acid and 4 µl of cupric sulfate solution was 
then added to each of the protein samples and the plate incubated at 37 °C for 30 min. 
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Fluorescence of the cell lysate in the 96-well black bottom plate was measured by a Tecan 




Excitation wavelength 486nm 
Emission wavelength 615nm 
Gain (Manual) 50 
Number of flashes 10 
Lag time 0 
Integration time 40 
Mirror selection Dichronic 2 
Z-position Adjust manually 
 
Protein measurements were performed analogously, with measurement mode “Absorbance” 
and an absorption wavelength of 570 nm. 
The relative fluorescent measurement unit (rfu) per milligram served as a relative scale that 
helped to quantify the amount of ASP+ taken up in the presence of inhibitor at different 
concentrations. It was determined by calculating the average rfu from the two measurements 
performed for each sample and extrapolated to 500 µl, the initial amount of cell lysate. The 
amount of protein per well was calculated from the degree of absorption of the samples 
within the 96-well plate. These values were corrected through the BSA standard and 
converted to milligrams. The quotient of rfu and protein in milligram (rfu/mg) represented 
ASP+ uptake and yielded absolute values, which were subsequently converted into relative 
values. The IC50 was calculated by equating the average amount of ASP
+ uptake by OCT1-
overexpressing cells in the wells without any inhibitor (i.e. non-inhibited ASP+ uptake) minus 
the uptake by the pcDNA5 cells (i.e. the baseline uptake) with 1,0. The amount of ASP+ 
uptake at all other concentrations was set in relation to this baseline. Their values were 
expressed in percent of non-inhibited ASP+ uptake and the percentages plotted as functions 
of their respective inhibitor concentration in a graph with SigmaPlot. The IC50s of the tested 
substances were also calculated with SigmaPlot by plotting the percentages as functions of 
their respective inhibitor concentrations and fitting a nonlinear regression curve through the 
graph.  
The ASP+ uptake inhibition experiments were conducted at least thrice in independent 
experiments for each of the test drugs. 
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2.2.6 Transport experiments 
The transport experiments were performed with OCT1-overexpressing HEK293 cell and 
two negative controls: pcDNA5 cells and OCT1-overexpressing cells supplemented with 
MPP+, an inhibitor of OCT1. 
Drug uptake was measured at three concentrations: 0.05, 0.1, and 0.5 µM. This was done 
once for pcDNA5 and twice for OCT1, one batch of which was supplemented with 2 mM 
MPP+, a potent inhibitor of OCT1, and served as an additional negative control. The three 
remaining wells –one with pcDNA5 and two with OCT1― were reserved for protein 
measurements (see Figure 4). 
Drug solutions were prepared at twice the desired concentration (i.e. 0.1, 0.2, and 1.0 µM) 
and the final concentrations obtained by adding an equal amount of either pure HBSS+ or 
HBSS+ spiked with 4 mM of MPP+ (which would be diluted to the desired concentration of 
2 mM, analogously to the ASP+ in the inhibition experiments). For a single experiment, 
0.75 ml of drug solution at double concentration was prepared for each drug. The stock 
solutions of 0.1, 0.2, and 1.0 µM were each split into 0.5 and 0.25 ml aliquots. 0.5 ml of pure 
HBSS+ was added to the 0.5ml aliquots, yielding 1ml of 0.05, 0.1, and 0.5 µM drug solutions, 
the volume sufficient for testing one pcDNA5 and one OCT1 well. 0.25 ml of HBSS+ 
containing 4 mM of MPP+ was added to the 0.25 ml aliquots, tallying up to 0.5 ml of 0.05, 
0.1, and 0.5 µM drug solutions with 2 mM MPP+ each that were added to the negative control 
OCT1 wells.  
In addition to the tested concentrations, a standard curve was prepared for each drug at 
concentrations of 0.1, 1, 10, and 100 nM. It was prepared in 80 % LC/MS-grade acetonitrile 
containing 10 ng/ml of an internal standard (IS), which varied depending on the substances 
tested (see 2.2.7, LC-MS). They underwent the same treatment as the samples did subsequent 




Figure 4: Plating and pipetting scheme for transport experiments, concentrations in µM 
Treatment before, during, and after drug uptake was the same as in the inhibition 
experiments. The solutions were warmed up to 37°C and 400 µl added to the wells every ten 
seconds, while the wells for protein measurement (the zero concentration wells, see Figure 4) 
remained in pure HBSS+. After incubating for two minutes, the cells were doused in 2 ml of 
ice-cold HBSS+ per well and all transport processes thus terminated. The wells were then 
washed two more times before the buffers were added to the cells. Analogously to the 
inhibition experiments, 500 µl of RIPA buffer was added to the zero concentration wells 
destined for protein measurement, whereas the cells incubated in drug solution were treated 
with 500 µl of acetonitrile/IS buffer. 
After placing the plates on the shaker for ten minutes, approx. 450 µl of the lysate (more if 
possible) were transferred from the wells on the plate and into test tubes. The samples, as 
well as the standards, were then centrifuged in a tabletop centrifuge at 13 x g for 10 min. 
350 µl of the supernatant was subsequently transferred into new, carefully labeled (!) test 
tubes. These tubes were either stored at -20 °C until testing or immediately processed further. 
For further processing, the tubes containing the samples were placed in a heating block and 
the samples evaporated with molecular nitrogen. Once the fluid had completely evaporated, 
the samples were resuspended in 350 µl of formic acid, vortexed, and centrifuged at 10 x g 
for 5 min. Finally, 100 µl of the centrifuged samples were transferred to LC-MS bottles and 
stored at 8 °C until measurement in the mass spectrometer  




The results of the LC-MS/MS measurement were given by the program in ng of detected 
drug per ml of eluent. These concentrations were converted into pmol/µl and extrapolated 
via the total volume of lysis buffer per well (500 µl/well) to pmol/well. The concentration 
of pmol/well was then divided by the amount of protein in mg per well and the incubation 
time of 2min, resulting in the uptake of measured drug in pmol/min/mg protein. 
2.2.7 LC-MS/MS 
Direct transport measurements were performed via mass spectrometry using an API4000 
LC-MS/MS system with the Analyst® Version 1.4.2 software. The samples were processed 
as described above and then subjected to measurements following the measurement 
protocols listed in Table 1. The mass-to-charge ratio of precursor and product ions were 
mostly obtained from the literature, but frequently supplemented with data from our own 
tuning process since we preferred to measure the mass-to-ratio values of at least two product 
ions when possible. The remaining parameters –retention time, mobile phase, flow– are also 




































3-Hydroxymorphinan 244.1/157.0 244.1/132.9 7.3' Nortilidine 260.3/155.1 8.3' 15 300 
3-Methoxymorphinan 258.4/215.1 258.4/171.2 8.4' Nortilidine 260.3/155.1 5.0' 20 500 
Codeine 300.3/215.1 300.3/165.1 4.8' Morphine 286.2/201.1 3.2' 8 300 
Dextromethorphan 272.2/171.1 272.2/215.2 8.1' Nortilidine 260.3/155.1 5.0' 20 500 
Dextrorphan 258.4/157.1 258.4/199.1 4.7' Nortilidine 260.3/155.1 5.0' 20 500 
Fentanyl 337.4/104.9 337.35/188.2 5.0' 3-Methoxymorphinan 258.4/215 5.4' 20 700 
Hydrocodone 300.5/199.1 300.5/128.1 6.8' Codeine  300.3/215.1 5.0' 8 300 
Hydromorphone 286.2/185.2 286.2/157.1 4.0' Codeine  300.3/215.1 5.0' 8 300 
Levorphanol 258.1/157.1 258.1/133.0 7.2' Nortilidine 260.3/155.1 8.3' 15 300 
Meptazinol 234.5/107.0 234.5/76.9 6.3' Nortilidine 260.3/155.1 7.9' 15 300 
Methylnaltrexone 356.2/338.2 356.2/284.1 5.6' Morphine 286.2/201.1 3.2' 8 300 
 356.2/338.2 356.2/284.1 3.6' Nortilidine 260.3/155.1 8.1' 15 300 
Morphine 286.2/201.1 286.2/165.1 3.2' Codeine  300.3/215.1 4.8' 8 300 
Naltrexone 342.3/324.2 342.3/270.1 6.3' Codeine  300.3/215.1 4.8' 8 300 
N-Desmethyltramadol 250.2/232.3 250.2/44.1 6.5' Norfentanyl 233.2/84.1 4.8' 15 300 
Norfentanyl 233.2/84.1 233.2/150.1 4.7' 
N-
Desmethyltramadol 250.2/232.3 6.4' 15 300 










Ion Analyte to 
Product Ion (m/z) 
Quantifier 
Precursor 




















Nortilidine 260.3/155.1 260.3/229.1 8.0' 
N-
Desmethyltramadol 250.2/232.3 6.5' 15 300 
Oxycodone 316.3/298.2 316.3/256.2 5.7' Codeine  300.3/215.1 4.8' 8 300 
Oxymorphone 302.3/284.1 302.3/277.1 3.7' Codeine  300.3/215.1 4.8' 8 300 
Pethidine (Meperidine) 248.4/174.1 248.4/91.0 8.0' Nortilidine 260.3/155.1 7.9' 15 300 
Sufentanil 387.2/238.1 387.15/110.9 10.5' 3-Methoxymorphinan 258.4/215 5.4' 20 700 



















m/z: mass-to-charge ratio. The mass-to-charge ratio for qualifier and quantifier precursor ion were obtained from Vengurlekar et al. (Vengurlekar et al. 2002) for 3-
hydroxymorphinan and 3-methoxymorphinan; from Eichhold et al. (Eichhold et al. 1997) for dextrorphan and dextromethorphan; from Fernandez et al. (Fernandez 
Mdel et al. 2013) for codeine, fentanyl, hydrocodone, hydromorphone, morphine, norfentanyl, oxycodone, and oxymorphone; from Bonn et al. (Bonn et al. 2010) for 
levorphanol; from Qiao et al. (Qiao et al. 2009) for meptazinol; from Oswald et al. (Oswald et al. 2011) for methylnaltrexone and naltrexone; from Godoy et al. (Godoy 
et al. 2011) for N-desmethyltramadol; from Fang et al. (Fang et al. 2013) for noroxycodone; from Köhler et al. (Kohler et al. 2011) for nortilidine and tilidine; from 






3.1 In silicio predictions 
We utilized in silico methods to narrow down the spectrum of possible OCT1 substrates by 
evaluating the pKa, logP, and logD(7.4) values of 60 opioids and excluding drugs with very 
high hydrophobicity. The average pKa, logP, and logD(7.4) of the complete set of opioids were 
8.52, 2.55, and 1.51, respectively (Table 2). The predicted pKa values lay between 6.71 and 
10.02, and only three substances (alfentanil, remifentanil, and naloxone) had pKa values 
below 7.4, indicating that overall the analyzed substances are moderate to strong bases and 
that, at a physiological pH in the range of 7.3-7.5, the equilibrium of 57 of the 60 substrates 
will favor an ionized state. LogP values ranged from -1.34 to 5.71, and logD(7.4) values from 
-1.57 to 4.66. 
Based on this data, we initially selected compounds with low logD(7.4) values for further 
analyses and then expanded the list of candidate substances to include commonly used 
opioids (e.g. fentanyl, logD(7.4) value of 3.47), opioid/metabolite pairs (e.g. 
oxycodone/noroxycodone), and opioids that, despite yielding high logD(7.4) values, bore a 
promising structural resemblance to established OCT1 substrates (e.g. similarity of 
meptazinol to O-desmethyltramadol).  
In this way, we selected a total of 23 opioid to undergo further experiments(Table 2). Their 
average pKa, logP, and logD(7.4) values were 8.68, 2.25, and 1.00, respectively. The average 
pKa and logP values of the complete set containing the original 60 substances and those of 
the experiment subset barely differ (+1.8 and -1.6%, respectively). In contrast, the average 
logD(7.4) value of the experiment subset was 33.8% lower than the average of the complete 





Table 2: Opioids and their predicted pKa, logP and logD(7.4) values, in alphabetical order  




analysis Reasons for inclusion 
3-Hydroxymorphinan 9.39 3 1.03 Yes 
Metabolite of 
dextromethorphan 
3-Methoxymorphinan 9.72 3.65 1.36 Yes 
Metabolite of 
dextromethorphan 
3-Monoacetylmorphine 8.23 1.13 0.21   
6-Monoacetylcodeine 8.24 1.84 0.94   
6-Monoacetylmorphine 8.1 1.39 0.62   
Alfentanil 6.71 2.26 2.18   
alpha-L-Acetylmethadol 9.01 4.83 3.21   
Alvimopan 7.9 0.73 0.61   
Buprenorphine 7.94 4.72 4.07   
Butorphanol 7.87 3.71 3.11   
Codeine 8.43 1.5 0.44 Yes 
Opioid used in clinical 
practice (cough syrups, 
analgesia), precursor of 
morphine  
Dextromethorphan 8.92 4.04 2.51 Yes 
Opioid used in clinical 
practice (cough syrups) 
Dextrorphan 8.81 3.34 1.92 Yes 
Metabolite of 
dextromethorphan 
Dezocine 8.99 3.36 1.77   
Dihydrocodeine 8.69 1.78 0.47   
Dihydromorphine 8.54 1.14 -0.02   
Dipipanone 9.08 4.78 3.1   
Diprenorphine 7.97 3.33 2.66   
D-Propoxyphene 8.77 4.74 3.35   
EDDP 8.77 4.98 3.59   
Ethorphine 8.04 3.09 2.36   
Fentanyl 8.23 4.36 3.47 Yes 
Opioid used in clinical 
practice (analgesia) 
Heronie (Diamorphine) 8.07 1.55 0.79   
Hydrocodone 8.59 1.54 0.32 Yes 
Opioid used in clinical 
practice (analgesia) 
Hydromorphone 8.43 1.09 0.04 Yes 
Opioid used in clinical 
practice (analgesia) 
Levorphanol 8.81 3.34 1.92 Yes 
Opioid used in clinical 
practice (analgesia), 
enantiomer of dextrorphan 
L-Methadone 9.1 3.92 2.21   
Lofentanil 7.64 4.46 4.02   
Loperamide 7.74 5.17 4.66   
32 
 




analysis Reasons for inclusion 
Meptazinol 8.9 3.36 1.85 Yes 
Opioid used in clinical 
practice (analgesia), 
chemical structure 
Methylnaltrexone 9.15 -1.27 -1.59 Yes 
Opioid used in clinical 
practice (OIBD), negative 
logD(7.4) (lowest of all) 
Morphine 8.3 0.9 -0.05 Yes 
Opioid used in clinical 
practice (analgesia), negative 
logD(7.4) 
Morphine-3-Glucuronide 8.41 -1.23 -1.27   
Morphine-6-Glucuronide 8.19 -1.34 -1.4   
Nalbuphine 7.63 1.83 1.4   
Nalmefene 7.72 2.6 2.11   
Nalorphine 7.78 1.65 1.12   
Naloxone 7.26 1.09 0.85   
Naltrexone 7.63 1.24 0.81 Yes 
Opioid used in clinical 
practice (antidote to opioid 
overdose) 
N-Desmethyltramadol 10.02 2.5 0.08 Yes Metabolite of tramadol 
Norbuprenorphine 9.1 3.34 1.64   
Norfentanyl 9.62 1.86 -0.33 Yes 
Metabolite of fentanyl, 
negative logD(7.4) 
Noroxycodone 8.82 0.41 -0.93 Yes 
Metabolite of oxycodone, 
negative logD(7.4) 
Norpethidine 9.69 2.16 0.16   
Norpropoxyphene 9.73 4.26 2.01   
Nortilidine 8.43 2.76 1.71 Yes 
Metabolite of tilidine (and 
active compound) 
O-Desmethyltramadol 8.98 2.19 0.6   
Oripavine 7.79 2.01 1.47   
Oxycodone 8 0.81 0.11 Yes 
Opioid used in clinical 
practice (analgesia) 
Oxymorphone 7.89 0.33 -0.28 Yes 
Opioid used in clinical 
practice (analgesia), negative 
logD(7.4) 
Pentazocine 8.23 4.25 3.36   
Pethidine (Meperidine) 8.91 2.45 0.93 Yes 
Opioid used in clinical 
practice (analgesia, to 
counter shivering), chemical 
structure 
Phenazocin 8.33 4.7 3.73   
Piritramide 7.57 3.48 3.08   
Remifentanil 7.25 1.96 1.73   
Sufentanil 7.78 3.91 3.38 Yes 
Opioid used in clinical 
practice (analgesia, esp. 
during general anesthesia) 
Tapentadol 9.29 3.27 1.39 Yes 




Thebaine 7.92 2.63 1.99   




analysis Reasons for inclusion 
Tilidine 7.64 3.33 2.89 Yes 
Opioid used in clinical 
practice (analgesia, prodrug) 
Tramadol 9.04 2.83 1.18   
  
 
    
AVERAGE (n=60) 8.43 2.55 1.51   
SEM ± 0.09 ± 0.20 ± 0.19   
AVERAGE (n=23) 8.68 2.51 1.00   
SEM ± 0.14 ± 0.30 ± 0.28   
Difference AVERAGES 
in % + 1.8 - 1.6 - 33.8   
 
SEM: standard error of the mean. The 23 opioids that were selected to undergo further experiments 
are marked in bold. Averages and SEMs of all 60 analyzed opioids are at the bottom of the table, 
along with the averages of the 23 opioids of the experiment subset. The difference between the 





3.2 Parallel artificial membrane assays (PAMPAs) 
We conducted the PAMPAs in order to establish in how far the in silicio logD(7.4) values 
corresponded to actual membrane permeability in an in vitro cell membrane model.  
The membrane permeabilities (Pe) of the 23 substances tested in the PAMPAs ranged across 
three potencies, from 0.002x10-5 (methylnaltrexone) to 6.4x10-5 (dextromethorphan). Despite 
the wide distribution, only six substances had values greater than 2x10-5. Seven substances 
had values smaller 0.5x10-5 (Table 3).  
All substances were tested in duplicate at three concentrations, except for morphine and 
codeine, which were only tested once at three concentrations. However, since their Pe’s 
correspond to those published previously by Tzvetkov et al. (5 ± 0.5 x10-7 versus our 1.58 ± 
0.1 x10-7 for morphine, and 8.2 ± 0.4 x10-6 versus our 8.01 ± 1.3 x10-6 for codeine (Tzvetkov 
et al. 2013)), we can assume that three measurements are sufficient to provide reliable Pe 
values.  
Determining the exact Pe values of the substances with the highest membrane permeability 
caused some difficulty. Because their Pe's lie close to equilibrium, even slight imprecisions in 
MS measurements led to CA becoming nominally larger than Cequil. In those cases, the formula 
used for calculating the Pe became invalid, so that the amount of data for the affected 
substances is not as large as we would have liked it to be. However, there was enough data 
to ensure that at least three individual Pe values contributed to the mean Pe of each substance 
presented. In addition, the high Pe's determined for dextromethorphan, fentanyl, pethidine, 
sufentanil, tilidine, and nortilidine are in line with established knowledge regarding their 
lipophilicity. 
Overall, the Pe values correspond to the predicted logD(7.4); however in the cases of 3-
hydroxymorphinan, dextrorphan, and levorphanol the experimentally determined Pe values 
are lower than the logD(7.4) values would originally have led us to expect. Conversely, 
oxycodone and pethidine yielded relatively high Pe values considering their logD(7.4) values. 
It follows that, while the logD(7.4) values are indicators of a substance’s lipophilicity, actual 













Methylnaltrexone 0.002 0.001 -1.59 
Morphine 0.016 0.001 -0.05 
3-Hydroxymorphinan 0.073 0.009 1.03 
 Noroxycodone 0.094 0.016 -0.93 
Hydromorphone 0.17 0.04 0.04 
Norfentanyl 0.26 0.07 -0.33 
Oxymorphone 0.32 0.16 -0.28 
Dextrorphan 0.54 0.16 1.92 
Codeine 0.80 0.13 0.44 
Hydrocodone 0.91 0.21 0.32 
Levorphanol 0.92 0.18 1.92 
N-Desmethyltramadol 1.3 0.32 0.08 
Tapentadol 1.4 0.26 1.39 
Meptazinol 1.4 0.35 1.85 
Naltrexone 1.5 0.22 0.81 
3-Methoxymorphinan 1.7 0.29 1.36 
Oxycodone 1.8 0.42 0.11 
Nortilidine 2.7 0.88 1.71 
Tilidine 3.2 1.2 2.89 
Sufentanil 3.8 0.59 3.38 
Pethidine (Meperidine) 4.0 0.72 0.93 
Fentanyl 5.7 0.10 3.47 
Dextromethorphan 6.4 0.71 2.51 
 
The PAMP assay simulated diffusion across a cell membrane under nearly physiological conditions 
(pH 7.4, ambient temperature of approx. 21°C). The substances are ranked from the substance with 
the smallest Pe down to the one with the largest. Opioids that emerged as substrates of OCT1 are 
printed in bold, opioids that emerged as inhibitors of OCT1 are highlighted in pale red. The smaller 
the partition coefficient Pe, the lower membrane permeability. The logD(7.4) values are the same as 






3.3 Inhibition experiments 
Twenty-three opioids were tested for their potency to inhibit OCT1. To this end, OCT1-
overexpressing cells were incubated with the model substrate ASP+ in the presence of 
increasing concentrations of opioids. An inhibitor was defined as a substance with an IC50 of 
100 µM or less, i.e. ASP+ uptake had to be reduced by 50 % or more at inhibitor 
concentrations of 100 µM or less. Fourteen inhibitors of OCT1 were identified in this 
manner (Table 4).  







Dextrorphan 6.40 1.63 
Levorphanol 8.48 0.60 
3-Methoxymorphinan 10.29 2.14 
Dextromethorphan 15.15 2.52 
Meptazinol 18.96 3.06 
Sufentanil 19.36 0.19 
Tapentadol 21.89 1.24 
Pethidine (Meperidine) 22.25 3.66 
3-Hydroxymorphinan 24.93 5.13 
Tilidine 38.71 13.95 
Fentanyl 46.17 6.81 
N-Desmethyltramadol 55.75 9.41 
Morphine 71.79 6.74 
Nortilidine 88.76 18.81 
Norfentanyl 117.74 16.56 
Hydromorphone 137.97 19.22 
Naltrexone 157.51 7.54 
Noroxycodone 199.82 22.27 
Methylnaltrexone 234.39 29.97 
Codeine 235.50 29.42 
Oxymorphone 250.33 35.24 
Hydrocodone 536.96 87.58 
Oxycodone 2003.78 172.90 
 
OCT1 substrates are marked in bold. The dashed line indicates the cut-off between IC50s lower and 






The inhibition curves of the tested substances are shown in Figure 5. The previously reported 
OCT1 substrate morphine had an IC50 of 71.8 ± 6.7 µM. Dextromethorphan and its 
derivatives were more potent OCT1-inhibitors than morphine and other morphinans with a 
more “morphine-like” structure (Fig. 8A and B). The group of synthetic opioids is mixed 
(Figs. C and D), but overall their IC50 values tend to lie below that of morphine, as do the 
IC50 values of the opioid receptor antagonists naltrexone and methylnaltrexone (Fig. E). 
The nine most potent inhibitors had IC50 values below 25 µM, ranging from dextrorphan 
(IC50 of 6.4 µM) to 3-hydroyxmorphinan (IC50 of 34.9 µM). Tilidine, fentanyl, N-
desmethyltramadol, morphine, and nortilidine also qualified as inhibitors. 
In contrast, the substances with the highest IC50 values -methylnaltrexone, codeine, 
oxymorphone, hydromorphone and especially oxycodone- spanned a range from 234 µM to 
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Figure 5: Comparative analyses of opioids as inhibitors of OCT1  
For better comparability, the substances were assigned to one of five different groups based on their 
structure and inhibitory potency. The first group (A) comprises those morphinans with a structure 
similar to morphine. The second group (B) is made up of dextromethorphan and its metabolites, plus 
levorphanol, the enantiomer of dextromethorphan-metabolite dextrorphan. Although they, too, are 
morphinans, they differ from morphine and the antagonists structurally in that they contain only four 
rings instead of five. The synthetic opioids (C and D) are structurally more heterogeneous than the 
morphinans and were distributed across two graphs to provide a better overview over the curves. 
The final group (E), the antagonists, are also morphine-like morphinans, but in contrast to the other 
opioids they act antagonistically upon opioid receptors. The morphine curve was added in black to 




3.4 Transport experiments 
3.4.1 Relative transport 
The main objective of this work was to determine which opioids may profit from OCT1 for 
their cellular uptake, i.e. which opioids are OCT1 substrates. To this end, we performed 
direct uptake measurements of the different opioids into OCT1-overexpressing cells via mass 
spectrometry. A substance was arbitrarily defined as a substrate if uptake of the substance 
into OCT1-overexpressing cells was at least 2.0 times as high as that into pcDNA5 cells at 
two or more of the three concentrations tested. In addition to the negative control pcDNA5 
cells, we also measured uptake in MPP+-inhibited OCT1-overexpressing cells to confirm that 
the values obtained from the pcDNA5 cells were the result of diffusion and not of some 
fault in the cell line.   
Overall, we assigned the tested substances to one of three groups: strong transport, moderate 
transport, and no transport. Out of 23 tested substances the transport experiment yielded -
next to the previously known morphine- seven further OCT1 substrates; three with strong 
transport and four with moderate transport.   
 
Strong transport 
Strong transport was defined as an at least five-fold increase of uptake of tested substance 
into OCT1-overexpressing cells compared to the negative control. In total, three substances 
strongly transported by OCT1 were identified: methylnaltrexone, 3-hydroxymorphinan, and 
norfentanyl (Table 5). The strongest increase in uptake was seen in methylnaltrexone, with a 
32-, 67-, and 85-fold increase in uptake at concentrations of 0.05, 0.1, and 0.5 µM, 
respectively. 3-Hydroxymorphinan experienced a 14 to 17-fold increase in uptake across the 
concentration range, while norfentanyl showed an approximately 7-fold increase in uptake at 



















































Figure 6: Relative increase in uptake of methylnaltrexone 
Negative control pcDNA5 cells, OCT1 cells, and OCT1 cells inhibited with 1 mM MPP+ were 
incubated with opioid solutions at concentrations of 0.05 µM, 0.1 µM, and 0.5 µM for two minutes 
and uptake of the opioid into the cells determined via LC-MS/MS. On the scale presented, the bars 
of the pcDNA5 cells and the OCT1 + 2 mM MPP+ cells are barely visible compared to the bars of 
the OCT1 cells. 
 
Moderate transport 
Moderate transport was defined as an at least two-fold, but less than five-fold increase in 
uptake of tested substance into OCT1-overexpressing cells compared to the negative control 
cells. Next to morphine, which has already been established as a substrate, four other 
substances were identified to be transported by OCT1 (Table 5). In descending order of 
uptake, these substances were morphine (maximally 5.1-fold increase), noroxycodone 
(maximally 4-fold increase), 3-methoxymorphinan (maximally 2.5-fold increase), meptazinol 
(maximally 2.3-fold increase, and hydromorphone (maximally 2-fold increase). 
 
No transport 
Transport activity was deemed non-existent when the uptake of substance into OCT1-
overexpressing cell was less than two times high as that into the negative controls. Codeine, 
dextromethorphan, dextrorphan, fentanyl, hydrocodone, levorphanol, naltrexone, 




Data on N-desmethyltramadol (the inactive M2 metabolite of tramadol) and nortilidine was 
inconclusive; whether or not and to what extent N-desmethyltramadol and nortilidine are 
transported by OCT1 could therefore not be determined.  
Table 5: Relative increase in uptake of tested substances  
 0.05 μM 0.1 μM 0.5 μM 
Substance Mean SEM Mean SEM Mean SEM 
3-Hydroxymorphinan 14.0 ±1.7 14.9 ±1.2 17.4 ±4.8 
3-Methoxymorphinan 2.5 ±0.7 2.2 ±0.4 2.0 0.1 
Codeine 0.7 ±0.2 1.0 ±0.3 0.8 ±0.0 
Dextromethorphan 1.1 ±0.2 1.3 ±0.4 0.8 ±0.2 
Dextrorphan 2.1 ±0.2 1.9 ±0.8 1.5 ±0.1 
Fentanyl 1.0 ±0.1 1.0 ±0.1 1.0 ±0.1 
Hydrocodone 0.9 ±0.1 1.6 ±0.3 1.2 ±0.1 
Hydromorphone 2.0 ±0.1 1.9 ±0.1 2.0 ±0.1 
Levorphanol 1.5 ±0.2 1.7 ±0.1 1.3 ±0.0 
Meptazinol 0.8 ±0.2 2.2 ±0.5 3.2 ±1.4 
Methylnaltrexone 32.4 ±20.4 67.9 ±39.8 85.9 ±24.7 
Morphine 4.6 ±0.5 5.1 ±0.7 4.3 ±0.7 
Naltrexone 0.8 ±0.2 0.8 ±0.2 1.0 ±0.2 
N-desmethyltramadol N.A. N.A. N.A. N.A. N.A. N.A. 
Norfentanyl 7.0 ±0.5 6.6 ±0.6 7.2 ±0.6 
Noroxycodone 4.0 ±1.4 3.9 ±0.3 3.6 ±0.1 
Nortilidine N.A. N.A. N.A. N.A. N.A. N.A. 
Oxycodone 0.9 ±0.0 0.8 ±0.1 0.9 ±0.0 
Oxymorphone 2.4 ±1.6 1.3 ±0.4 0.9 ±0.2 
Pethidine (Meperidine) 1.1 ±0.1 1.2 ±0.1 1.2 ±0.1 
Sufentanil 1.1 ±0.0 1.0 ±0.1 1.1 ±0.1 
Tapentadol 0.9 ±0.2 1.6 ±0.3 1.5 ±0.2 
Tilidine 1.3 ±0.2 1.3 ±0.3 1.3 ±0.1 
       
The relative increase of substrate into OCT1-overexpressing cells was calculated in relation to the 
negative control cells at concentrations of 0.05, 0.1, and 0.5μM. Substances identified as substrates 
of OCT1 are highlighted in pale green. 
 
3.4.2 Absolute transport 
The absolute transport of the different opioids into the different cells lines is of less interest 
than the relative uptake; nevertheless, the data are included in Table 6 in order to supplement 








Table 6: Absolute uptake of the tested substance  
 Uptake in pmol/min/mg protein 
 pcDNA 0.05 pcDNA 0.1 pcDNA 0.5 OCT 1 0.05 OCT 1 0.1 OCT1 0.5 
OCT1 0.05 + 
MPP+ 
OCT1 0.1 + 
MPP+ 
OCT1 0.5 + 
MPP+ 
3-Hydroxymorphinan 168.5 333.7 1852.3 2324.2 4857.0 30594.4 209.1 418.0 2601.9 
 ±16.5 ±50.8 ±168.1 ±198.2 ±376.6 ±5098.1 ±14.4 ±21.3 ±78.8 
3-Methoxymorphinan 3950.1 2706.4 18262.3 6903.9 6246.3 37657.1 3849.1 4581.9 30503.0 
 ±2169.5 ±746.1 ±4635.4 ±1343.8 ±1942.0 ±10295.7 ±1057.1 ±1358.3 ±11154.5 
Codeine 434.0 909.5 4281.8 322.7 749.9 3499.0 567.9 734.7 4389.3 
 ±82.3 ±270.8 ±1027.8 ±131.5 ±100.5 ±774.9 ±318.2 ±114.3 ±1227.4 
Dextromethorphan 2417.9 6314.6 30502.3 2692.5 9233.4 21134.0 2539.8 4375.0 24182.7 
 ±622.4 ±2575.9 ±9044.0 ±1055.3 ±5900.6 ±4605.1 ±940.2 ±1382.9 ±6976.0 
Dextrorphan 897.5 2613.0 11808.0 2357.3 5897.5 17326.3 1284.3 2037.2 11235.1 
 ±151.7 ±919.7 ±4056.5 ±479.4 ±1663.0 ±5610.3 ±179.8 ±588.0 ±2397.8 
Fentanyl 591.1 1153.6 5488.4 604.3 1127.8 5402.9 497.4 872.1 5009.9 
 ±177.6 ±199.3 ±727.0 ±155.5 ±198.5 ±746.6 ±145.8 ±165.5 ±760.2 
Hydrocodone 80.8 176.4 1751.0 77.9 265.0 2175.8 85.0 223.9 1761.6 
 ±18.8 ±25.7 ±153.0 ±27.9 ±40.9 ±308.7 ±18.9 ±32.6 ±271.6 
Hydromorphone 95.5 196.5 1089.8 193.3 371.6 2158.1 95.0 175.3 991.6 
 ±2.2 ±9.2 ±86.6 ±13.6 ±22.3 ±102.2 ±1.2 ±2.3 ±83.4 
Levorphanol 1215.3 1457.6 8104.7 1339.6 2427.6 10654.0 795.7 2146.2 8098.2 
 ±503.5 ±137.9 ±777.7 ±190.7 ±213.1 ±1297.4 ±85.5 ±728.8 ±587.1 
Meptazinol 599.0 806.1 3930.5 415.2 1645.5 13038.5 356.6 884.2 3353.4 
 ±170.0 ±148.1 ±874.2 ±50.7 ±373.9 ±5564.5 ±98.0 ±167.1 ±355.3 
Methylnaltrexone 71.2 54.3 261.0 1061.2 2374.6 19269.2 61.6 86.6 427.1 







Morphine 141.8 257.5 1367.0 654.0 1324.8 5803.9 102.4 440.9 872.0 
 ±7.9 ±8.7 ±146.0 ±52.4 ±180.1 ±620.1 ±3.2 ±249.9 ±104.4 
Naltrexone 380.5 788.9 3949.2 274.9 596.1 4133.9 301.1 720.9 4452.6 
 ±113.7 ±31.6 ±87.8 ±11.4 ±107.6 ±908.1 ±70.1 ±130.5 ±1093.3 
N-desmethyltramadol N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. 
 N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. 
Norfentanyl 109.9 232.1 1189.6 757.4 1503.8 8554.4 105.0 185.8 875.3 
 ±12.8 ±17.8 ±56.3 ±50.9 ±21.8 ±621.9 ±16.5 ±7.3 ±21.3 
Noroxycodone 94.0 163.8 979.2 320.5 623.9 3496.0 45.4 120.1 755.1 
 ±20.1 ±24.4 ±29.5 ±58.5 ±39.7 ±45.5 ±21.8 ±20.9 ±31.6 
Nortilidine N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. 
 N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. 
Oxycodone 227.0 463.1 2402.4 212.1 370.3 2212.5 56.6 183.9 1083.6 
 ±28.3 ±25.5 ±247.6 ±22.3 ±40.7 ±272.1 ±28.5 ±41.6 ±158.2 
Oxymorphone 114.2 857.0 1849.4 189.0 761.2 1568.0 470.9 605.7 2021.8 
 ±98.1 ±408.9 ±87.1 ±17.6 ±295.1 ±366.4 ±272.3 ±365.3 ±283.5 
Pethidine 458.1 806.5 5177.4 503.5 959.0 5728.5 579.7 1120.8 5502.8 
 ±154.5 ±231.3 ±1777.5 ±149.8 ±188.9 ±1162.8 ±181.5 ±289.3 ±1299.8 
Sufenanil 849.2 2040.3 11525.7 931.8 2105.2 12482.4 718.7 1895.6 11161.1 
 ±77.2 ±99.3 ±776.0 ±107.9 ±217.6 ±2033.8 ±138.1 ±303.0 ±1853.8 
Tapentadol 1070.0 1886.5 10534.1 944.1 2921.7 15453.2 963.3 1553.6 8182.0 
 ±89.1 ±572.3 ±1581.6 ±244.2 ±854.4 ±2753.6 ±276.1 ±343.7 ±1888.1 
Tilidine 171.0 312.7 1704.4 229.8 437.2 2158.1 215.5 350.3 2041.6 
 ±19.3 ±30.5 ±319.9 ±56.8 ±132.4 ±496.7 ±47.9 ±118.4 ±687.1 
Printed above in each cell is the average uptake of substrate in pmol/min/mg; below are the respective SEMs. OCT1 substrates are highlighted in green. N.A. (not available): the 




We will discuss the results of our experiments under four aspects: pharmaco-clinical 
properties, structural aspects, aspects of metabolism, and clinical aspects. 
4.1 Pharmaco-chemical properties 
In order to better evaluate our findings regarding pKa, logD(7.4), and Pe, we are going to 
explore these parameters under the aspects of OCT1 transport (OCT1 substrates vs. non-
substrates), OCT1 inhibition (OCT inhibitors vs. non-inhibitors), and pharmacologic class 
(morphinans vs. synthetic opioids).  
Substrates vs. non-substrates 
A histogram of the pKa values of OCT1 substrates compared to those of non-substrates 
yielded no marked difference between the two groups (Figure 7), though the substrates’ 
average pKa lay slightly above that of the non-substrates, with 9.04 and 8.49, respectively 
(Table 7). 
With respect to logD(7.4) , substrates of OCT1 displayed lower values than non-substrates, 
with substrates yielding an average logD(7.4) of 0.17 and non-substrates of 1.44 (p=0.026, 
Table 7). This was to be expected since only substances with low lipophilicity and presumed 
low membrane permeability would require a transporter to enable their uptake into cells. 
This finding was further bolstered by the results of the substrates’ and non-substrates’ Pe 
values. With a value of 0.47x10-5, the average Pe’s of the substrates is considerably lower than 
that of the non-substrates, which lies at 2.35x10-5 (p=0.013, Table 7). Of the seven substances 
with Pe values below 5x10
-6, six are substrates of OCT1. The two substrates of OCT1 with 
larger Pe values, meptazinol and 3-methoxymorphinan, lay between 1.4 and 1.7x10
-5 (see 
Table 3, section 3.2). The Pe values of non-substrates were evenly spread across the spectrum 
(Figure 9). 
These results nicely illustrate that substances with low membrane permeability are more likely 
to be substrates of OCT1 than those with high logD(7.4) and Pe values. 
Inhibitors vs. non-inhibitors 
At 8.80 and 8.51, the average pKa’s of inhibitors and non-inhibitors happen to be very similar. 
Their average logD(7.4) and Pe values, however, differ markedly. While the average logD(7.4) 
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and Pe values of the inhibitors were 3.16 and 1.74, respectively, those of the non-inhibitors 
lay far below that, with a logD(7.4) of 0.83 and a Pe value of -0.16 (p=0.00014 and p=0.023, 
respectively, Table 7). The histogram in Figure 9 especially illustrates that non-inhibitors have 
low Pe values, whereas inhibitors span the entire spectrum.  
It appears that, while low logD(7.4) and Pe values are common in substrates of OCT1, they 
also correlate with a low probability for inhibitory potential. 
Morphinans vs. synthetic opioids  
Following fourteen substances are morphinans: morphine, codeine, oxycodone, 
oxymorphone, hydrocodone, hydromorphone, noroxycodone, naltrexone, and 
methlynaltrexone as well as dextromethorphan, dextrorphan, levorphanol, 3-
methoxymorphinan, and 3-hydroxymorphinan. Opposed to the morphinans are the 
synthetic opioids and their metabolites, whose chemical structure bears no resemblance to 
the polycyclic structure of the morphinans. The group of synthetic opioids was made up by 
nine substances: fentanyl, meptazinol, N-desmethyltramadol, norfentanyl, nortilidine, 
pethidine, sufentanil, tapentadol, and tilidine. 
While there is little difference in the pKa values of morphinans and synthetic opioids (8.64 
and 8.74, respectively; p=0.675), the average logD(7.4) of the synthetic opioids lay above that 
of the morphinans, with values of 1.94 and 0.54, respectively (p=0.038, Table 7, Figure 7, and 
Figure 8). These values indicate that synthetic opioids are more lipophilic than the classic 
morphinans, which is indeed their purpose. Synthetic opioids were designed to be more 
potent than classic opioid, and higher lipophilicity means these opioids can cross the blood-
brain barrier more easily and have a more powerful effect on the central nervous system. In 
comparison, the difference between the Pe values of morphinans and synthetic opioids seems 
less marked (1.09 and 2.64, respectively; p=0.042); however, the discrepancy in the 
distribution of their Pe values becomes visible in Figure 9, with the morphinans clearly 
clustered around low Pe values. Dextromethorphan, on the far right of the x-achsis, is the 
only morphinan with a Pe value larger 2x10
-5 (Figure 9). In contrast, the Pe values of the 
synthetic opioids did not fall below 1x10-5. 
Methylnaltrexone yielded the lowest Pe (0.002 ± 0.001x10
-5) by far, indicating very poor 
membrane permeability. It was followed by morphine, 3-hydroxymorphinan, noroxycodone, 
hydromorphone, and norfentanyl, all of which are substrates of OCT1, and all of which, 
except for norfentanyl, are morphinans.  
46 
 
Overall, OCT1 substrates, non-inhibitors, and morphinans have significantly lower logD(7.4) 
and Pe values than their respective counterparts. Opioids with low lipophilicity are therefore 
more likely to be a substrate of OCT1, a non-inhibitor, or a morphinan (or a combination 
thereof) while more lipophilic opioids are more likely to be non-substrates, inhibitors, and 




Table 7: pKa, logD(7.4), and Pe values and their significance 
Opioid pKa logD(7.4) Pe x10-5 
3-Hydroxymorphinan 9.39 1.03 0.073 
3-Methoxymorphinan 9.72 1.36 1.7 
Codeine 8.43 0.44 0.80 
Dextromethorphan 8.92 2.51 6.4 
Dextrorphan 8.81 1.92 0.54 
Fentanyl 8.23 3.47 5.7 
Hydrocodone 8.59 0.32 0.91 
Hydromorphone 8.43 0.04 0.17 
Levorphanol 8.81 1.92 0.92 
Meptazinol 8.90 1.85 1.4 
Methylnaltrexone 9.15 -1.59 0.002 
Morphine 8.30 -0.05 0.016 
Naltrexone 7.63 0.81 1.5 
N-Desmethyltramadol 10.02 0.08 1.3 
Norfentanyl 9.62 -0.33 0.26 
Noroxycodone 8.82 -0.93 0.094 
Nortilidine 8.43 1.71 2.7 
Oxycodone 8.00 0.11 1.8 
Oxymorphone 7.89 -0.28 0.32 
Pethidine (Meperidine) 
8.91 0.93 4.0 
Sufentanil 7.78 3.38 3.8 
Tapentadol 9.29 1.39 1.4 
Tilidine 7.64 2.89 3.2 
    
Average Total 8.68 1.00 1.70 
    
Average substrates 9.04 0.17 0.47 
Average non-substrates 8.49 1.44 2.35 
Significance (p-value) 0.057 0.026 0.013 
    
Average inhibitors 8.80 1.74 2.37 
Average non-inhibitors 8.51 -0.16 0.65 
Significance (p-value) 0,318 0,00014 0,023 
    
Average morphinans 8.64 0.54 1.09 
Average synthetic opioids 8.76 1.71 2.64 
Significance (p-value) 0.675 0.038 0.042 
The averages are given in bold, along with the significance of the differences between the averages 
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Figure 10: Histograms of IC50 values for OCT1 substrates and non-substrates, morphinans and synthetic opioids, and OCT1 inhibitors and non-inhibitors 




4.2 Structural aspects 
In the following we shall discuss which structural aspects might predispose a substance to be 
either a substrate of OCT1 or an inhibitor of OCT1, or to have no observed interaction with 
OCT1.  
Substrates 
Six of eight substrates are opioids with a morphinan structure. The two exceptions are 
meptazinol, a synthetic opioid, and norfentanyl, metabolite of the synthetic opioid fentanyl. 
Norfentanyl, despite being a synthetic opioid, resembles the morphinans in its chemical 
properties more than it does the synthetic opioids (see Table 7, section 4.1). 
Despite obvious shared characteristics (polycyclic structure, aromatic ring), a common 
denominator that singles out these opioids as substrates in contrast to, for example, 
dextrorphan or oxycodone, remains elusive.  
 
 





Synthetic opioids and their metabolites make up more than half the roster of inhibitors; of 
the fourteen inhibitors, eight are synthetic. Of the six inhibitors with a morphinan structure, 
morphine is the only “classic” morphinan; the other five inhibitors are dextromethorphan 
and its metabolites.  
As mentioned in the introduction, substances with an inhibitory effect on OCT1 have 
different qualities in common. One of them is lipophilicity. The results from our PAMP 
assays confirm that the opioids identified by us as inhibitors are indeed more lipophilic than 
those that did not inhibit OCT1 (see Table 7). Additionally, all our inhibitors are at least 
partially charged at a physiological pH and have a relative dearth of hydrogen-bonding 
moieties (Figure 12). The properties intrinsic to our set of inhibitors are therefore in keeping 
with the model developed by Ahlin et al. (Ahlin et al. 2008).  
As can be seen in Figure 13 and Figure 14, synthetic opioids and dextromethorphan-like 
morphinans interact strongly with OCT1. The dextromethrophans interact even more 
strongly than the synthetic opioids; of the five inhibitors with IC50 values below 20 µM, four 
are dextromethorphan-like morphinans. But again, we cannot name a specific moiety 












Figure 13: Synthetic opioids and their respective IC50 values  
Normal arrows indicate a metabolic, dashed arrows a structural relationship. Tramadol und O-desmethyltramadol have been discussed elsewhere (Tzvetkov et 




Figure 14: Morphinans and their respective IC50 values  




No observed interaction 
Five substances did not observably interact with OCT1 either in the way of substrates or in 




Figure 15: Opioids with no observed interaction with OCT1 
The observation that naltrexone does not interact with OCT1 is surprising because only a 
methyl group at the nitrogen atom distinguishes it structurally from methylnaltrexone, which 
proved to depend heavily on OCT1-mediated transport. However, with a Pe of 1.5x10
-5 
naltrexone is a lot more lipophilic than methylnaltrexone (Pe of 0.002x10
-5). It remains 
similarly mystifying why hydromorphone should be a substrate of OCT1 while 
oxymorphone is not, or why noroxycodone relies on OCT1-mediated transport while 






4.3 Aspects of metabolism  
Six of the eight substances we identified as OCT1 substrates are metabolites of other opioids: 
3-methoxymorphinan and 3-hydroxymorphinan are metabolites of dextromethorphan; 
hydromorphone is a metabolite of hydrocodone, morphine of codeine, noroxycodone of 
oxycodone, and norfentanyl of fentanyl. At the same time, four of the substances –3-
methoxymorphinan, morphine, meptazinol and hydromorphone– are amenable to further 
metabolization, i.e. they are parent compounds themselves. These four compounds are active 
until biotransformation, mainly hepatocytic glucuronidation, leads to their inactivation (see 
Appendix for more detail).  
We observed that uptake of metabolite opioids by OCT1-overexpressing cells was elevated 
compared to that of their parent compounds, which were often not transported by OCT1 at 
all (Figure 16). A possible explanation for this observation is that biotransformation renders 
opioids more hydrophilic and thus more dependent on transporter-mediated uptake and 
release from hepatocytes, whereas the parent compounds are more lipophilic and thus 
capable of crossing cell membranes independently of OCT1 via diffusion. 
The metabolic progression of dextromethorphan and its metabolites in Figure 16 nicely 
illustrates how OCT1-mediated transport progresses with each modification introduced by 
biotransformation. Unfortunately, we lack data on OCT1-mediated transport -if present- of 
the glucuronidated metabolites of hydromorphone, meptazinol, and morphine. It would be 
interesting to see if OCT1-mediated transport of their metabolites increases in the same 
























































































































































































































































































































































































































































Figure 16: Uptake of parent compounds and their metabolites  
(A) Progressive increase in OCT1-dependent uptake of dextromethorphan and its metabolites. (B) 
Uptake is only increased for oxycodone metabolite noroxycodone, not for its alternative metabolite 
oxymorphone. (C) Uptake of fentanyl is not altered in the presence of OCT1 but that of its metabolite 
norfentanyl is. (D) OCT1-dependent transport of hydromorphone is increased compared to that of 




4.4 Clinical aspects 
Identifying opioids as either substrates or inhibitors of OCT1 is not merely an exercise born 
from academic interest; it is also an attempt to understand –and possibly predict– how 
opioids administered in a clinical setting may affect patients. We shall therefore now discuss 
the ramifications of our findings and attempt to put them into a practical context. 
Substrates 
Morphine aside, we identified seven novel substrates, three of which act upon opioid 
receptors: hydromorphone, meptazinol, and methylnaltrexone. The other four –3-
hydroxymorphinan, 3-methoxymorphinan, norfentanyl, and noroxycodone– are considered 
inactive with respect to opioid receptor activity.  
The relative increase in the uptake of hydromorphone was the lowest of all substrates. Taking 
into account that the absolute uptake of oxycodone –not a substrate of OCT1– into OCT1-
overexpressing cells was equal to that of hydromorphone, it seems highly improbable that 
OCT1 polymorphisms would have a clinically noticeable impact on hydromorphone plasma 
concentrations. However, hydromorphone is a widely employed analgesic, and the impact of 
OCT1 polymorphisms on its metabolization, however marginal, should not be easily 
dismissed.  
Meptazinol is the most lipophilic of the substrates, and the only active member of the class 
of synthetic opioids that qualifies as a substrate. It is also extensively metabolized by the liver, 
so that OCT1 might indeed play a role in its phase 0 biotransformation and elimination 
(Franklin et al. 1975). It would be worth investigating if and in how far plasma concentrations 
of meptazinol are affected by diminished OCT1 transport capacities.  
Methylnaltrexone turned out to rely heavily on OCT1-mediated transport. Though 
methylnaltrexone interacted poorly with OCT1 in the presence of ASP+ and failed to qualify 
as an inhibitor by a wide margin (IC50 of 234.39 µM), its uptake via OCT1 skyrocketed in the 
absence of competing substrates. Assumedly, when in direct competition for the binding site 
that mediates transportation, ASP+ binds more efficiently to OCT1 than methylnaltrexone. 
Otherwise the fact that methylnaltrexone is transported by OCT1 came not entirely 
surprising, considering that methylnaltrexone’s quaternary nitrogen atom and low membrane 
permeability essentially render it unsuitable for diffusion. The relative increase in uptake (32x, 
68x, and 86x) was impressive nevertheless (see Figure 6, section 3.4.1).  
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It also remains uncertain in how far OCT1-mediated transport of methylnaltrexone into the 
liver is clinically relevant, considering that 60% of methylnaltrexone are excreted unchanged 
and thus independently of hepatic biotransformation (see Appendix for more detail). Instead, 
methylnaltrexone might play a greater role in research as a new, highly sensitive model 
substrate for OCT1.  
The other substrates do not currently have any confirmed clinical effects. Even if their 
plasma concentrations were affected by diminished OCT1 transport capacities, the 
consequences of such diminished transport would bear little or no clinical relevancy.  
Inhibitors 
Though our main interest initially lay with the substrates of OCT1, our results gradually 
shifted our focus to the inhibitors. Since OCT1 is one of the transporters most involved in 
the metabolism of a wide range of drugs, the opioids identified by us as inhibitors of OCT1 
have at least the potential to affect the transport of such drugs into OCT1-expressing cells.  
In order to assess which of the inhibitors might, at least in theory, affect OCT1-mediated 
uptake in vivo, we calculated the ratio of the opioids’ maximal unbound plasma concentration 
in the portal vein and our experimentally determined IC50 values as described elsewhere (Ito 
et al. 2002; Ahlin et al. 2011). These calculations are of interest in so far as they attempt to 
translate our findings from an in vitro set up into an in vivo environment. However, they cannot 
level out the experimental nature of our findings entirely.  
The IC50s were determined by measuring how effectively they inhibited the uptake of a test 
substrate. In our case, this test substrate was ASP+, which yielded an IC50 of 72 µM for 
morphine. This value is more than fifteen-times as high as the 4.2 µM reported by Tzvetkov 
et al.; however, latter determined the IC50 of morphine using the model substrate MPP
+ and 
liquid scintillating counting (Tzvetkov et al. 2013). So while the calculations presented in 
Table 8 nudge us into promising directions in terms of future research, the opioids’ Km and 
Vmax are needed in order to fully appreciate their effects on OCT1. 
Of the fourteen in vitro inhibitors, dextromethorphan, levorphanol, and tapentadol emerged 
as candidates that may be potent enough at clinically realistic plasma concentrations to inhibit 
OCT1 in vivo. Tapentadol yielded especially high ratios in both the immediate and extended 
release formulation (0.86 and 0.88, respectively) as did levorphanol (0.88) when administered 
repeatedly. Tapentadol and levorphanol are both opioids employed in chronic pain 
management, which means that they are likely to reach steady-state concentrations and that, 
due to the respective patient population, they are likely to be co-administered along with 
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other drugs, which may well rely on OCT1-mediated uptake for metabolization (e.g. the anti-
emetic odansetron). Further studies would be needed to confirm or invalidate such 
interactions in actual patients, but given the broad spectrum of available opioids, our 
experimental data may invite clinicians to defer from administering tapentadol and 
levorphanol in favor of opioids such as oxycodone or hydrocodone (always provided the 
patients tolerate them). 
Dextromethorphan -somewhat confusingly on first glance- only seems to have an effect in 
extensive metabolizers of CYP2D6. The CYP2D6 genotype should not affect the portal 
venous concentrations of dextromethorphan, since the drug has only just been absorbed 
from the gut and not yet been metabolized by the liver (and even if we assumed we had 
reached steady-state plasma concentrations after repeated dosing, we would expect the 
concentration of dextromethorphan to be higher in poor than in extensive metabolizer). 
However, in the studies from which we took the plasma concentrations for 
dextromethorphan, test subjects with a known PM CYP2D6 genotype were given lower 
doses of dextromethorphan than those with an EM CYP2D6 genotype (Thummel et al. 
2005). It is fair to assume that, had the PMs been given the same dose of dextromethorphan 
as the EMs rather than just half of it, that their portal venous concentration of 
dextromethorphan would have equalled that of the EMs. We can only speculate that patients 
with a PM CYP2D6 genotype, since less effective at metabolizing dextromethorphan, will 
suffer prolonged inhibition of OCT1. But since patients have unchecked access to cough 
syrups with dextromethorphan and the PM CYP2D6 is relatively common in the Caucasian 
population, it would be well worth it to further explore the inhibitory effects of 











Table 8: Inhibition of OCT1-mediated uptake by opioids identified as inhibitors of OCT1 in vitro 
Enteral administration       
Inhibitor IC50, µM Dose p.o., mg 
 Plasma conc. 
max, µg/l  
 Plasma conc. 
max, µM Cmax portal unb., µM Cmax portal unb/IC50 
Dextromethorphan EM 15.1 60 5.2 0.019 4.813 0.318 
Dextromethorphan PM 15.1 30 33 0.122 2.446 0.161 
Levorphanol, repeated dose 8.5 50 10 0.039 7.473 0.881 
Levorphanol, single dose 8.5 2 100 0.389 0.313 0.037 
Morphine IR, single dose 71.8 10 10 0.035 1.438 0.020 
Morphine ER, single dose 71.8 50 7.4 0.026 7.091 0.099 
Tapentadol IR 21.9 86 22.5 0.102 19.539 0.892 
Tapentadol ER 21.9 86 64.2 0.290 19.388 0.886 
Tilidine 38.7 50 30 0.110 8.029 0.207 
       
       
Parenteral administration       
Inhibitor IC50, µM Dose, mg 
 Plasma conc. 
max, µg/l  
 Plasma conc. 
max, µM Cmax portal unb., µM Cmax portal unb/IC50 
Fentanyl 46.2 0,4mg t.m. 0.8 0.002 < 0.000 < 0.000 
Meptazinol 19.0 25mg i.v. 90 0.386 0.104 0.005 
Morphine 71.8 10mg i.v. 400 1.402 0.911 0.013 
Pethidine (Meperidine) 
22.3 24mg/hr i.v. to 
steady state 
670 2.709 1.138 0.051 
Sufentanil 19.4 i.v. 10 0.026 0.002 0.000 
Tilidine 38.7 50mg i.v. 906 3.314 2.320 0.060 
In order to assess the inhibitory potential of the opioids, we calculated the ratio of the opioids’ maximal unbound concentration in the portal vein and the experimentally 
determined IC50 values. Ratios greater 0.25 indicate inhibitory potential. In parenteral administration, the peripheral plasma concentrations are equivalent to portal venous 
concentrations; calculating the portal venous concentration was therefore not necessary. Data on 3-hydroxymorphinan, 3-methoxymorphinan, dextrorphan, N-







Cmax plasma unb., maximal concentrations of the unbound drug in plasma; Cmax portal unb., maximal concentrations of the unbound drug in portal vein; EM, extensive 
metabolizer (regarding CYP2D6); PM, poor metabolizer (regarding CYP2D6); IR, immediate release; ER, extended (sustained) release; N.A., not available 
aThe maximal plasma concentration of the unbound drug (Cmax plasma unb.) was calculated by multiplying the Cmax by the fraction unbound in plasma. The maximal 
plasma concentrations and the fraction unbound to plasma proteins were obtained from Gilman and Goodman’s The Pharmacological Basis of Therapeutics (Thummel 
et al. 2005) for fentanyl, morphine, and pethidine; from Gilman and Goodman’s The Pharmacological Basis of Therapeutics (Thummel et al. 2005) and Taylor (Taylor 
et al. 2016) for dextromethorphan; from Hajda et al (Hajda et al. 2002) for tilidine; from the FDA’s Professional Drug Information (FDA) and Dixon et al (Dixon et al. 
1983) for levorphanol; from Gohler et al (Göhler et al. 2013) for tapentadol; and from Opioids in Cancer Pain (Hall and Hardy 2009) and Schmerztherapie (Standle et 
al. 2010) for sufentanil. 





We were able to identify seven novel substrates of OCT1, three of which could be relevant 
in a clinical context should they be affected by diminished OCT1 transport capacities, and 
fourteen inhibitors of OCT1, again three of which could affect OCT1-mediated transport in 
vivo.  
From the point of view of OCT1 and its polymorphisms, we were able to identify five opioids 
–namely codeine, hydrocodone, naltrexone, oxycodone, and oxymorphone– as clinically 
“safe” opioids, i.e. as opioids that interact neither as substrates nor inhibitors with OCT1. 
Since they have no touching points with OCT1, we can expect plasma concentrations of 
these opioids to go unaffected by variegations in OCT1 transport capacities, whether brought 
about by either genetic variations or by pharmacologic interactions. Nor would we expect 
them to affect the plasma concentrations of drugs dependent on OCT1-mediated transport. 
However, we only dealt with wild type OCT1 in our experiments and cannot exclude that 
these opioids do not interact with certain variations of OCT1. Further testing would be 
needed in order to elucidate if these opioids are indeed “genetically indifferent” as far as 
variations in SLC22A1 are concerned. 
From a chemical point of view, our results yielded that low lipophilicity –in the semblance 
of low logD(7.4) and Pe values– increase the probability that a given opioid will be an OCT1 
substrate, a non-inhibitor, and a morphinan, while high lipophilicity can be associated with 
non-substrates, inhibitors, and synthetic opioids. Additionally, the class of synthetic opioids 
and the one of dextromethorphan-like morphinans –which are mostly lipophilic substances– 
turned out to be especially potent inhibitors of OCT1 in vitro, whereas morphine-like 
morphinans –generally less lipophilic opioids– inhibit OCT1 transport capabilities only to a 
moderate degree. However, we are as yet unable to pinpoint a specific moiety or structural 
quirk that flags a drug as either substrate or inhibitor.  
All in all, further experiments will be needed to elucidate the interactions between inhibitors 
and substrates with OCT1 and each other. Inhibitor-substrate interactions should be 
evaluated in OCT1 non-overexpressing cells (e.g. human hepatocytes) and at therapeutic 
concentrations (e.g. OCT1 inhibitor tapentadol in combination with OCT1 substrate 
rocuronium) to elucidate if and to what extent the opioids identified as potent inhibitors of 
OCT1 affect OCT1-mediated uptake of other substances. The most common OCT1 variants 




The organic cation transporter 1 (OCT1) is primarily located in the sinusoidal membranes of 
hepatocytes and mediates phase 0 biotransformation of xenobiotics, including weak basic 
and cationic drugs. Variations in SLC22A1, the gene encoding OCT1, are common 
throughout the Caucasian population. Close to 9% of Caucasians are homozygotic for OCT1 
alleles that encode insufficient transporters, resulting in a partial or complete loss of OCT1 
transport activity in affected individuals. Clinical studies have demonstrated that diminished 
OCT1 transport activity leads to elevated plasma levels of opioids morphine and O-
desmethyltramadol (the active metabolite of tramadol). Patients with diminished-activity 
OCT1 alleles require 20% less tramadol for efficient postoperative pain management and 
suffer more adverse effects after morphine consumption. These findings are all the more 
relevant when considering the high prevalence of diminished-activity OCT1 variants and the 
extensive use of opioids in clinical practice. 
The aim of this study was to perform a systematic screening of opioids in vitro in order to 
identify substrates and inhibitors of OCT1 beyond morphine and tramadol that might be 
affected by reduced OCT1 activity. The screening was performed in a four-step process that 
involved in silicio predictions, membrane permeability testing in an artificial membrane model 
(so-called parallel artificial membrane permeability assays), inhibition experiments, and 
transport experiments. For the inhibition experiments, we photometrically determined to 
what extent our test drugs inhibited the uptake of the fluorescent OCT1 substrate ASP+, 
while for the transport experiments we measured the uptake of test drugs into OCT1-
overexpressing HEK293 cells directly via LC-MS/MS. Sixty opioids underwent the initial in 
silicio predictions; of those, we chose 23 opioids to run the entire course of experiments. 
Seven novel substrates and fourteen inhibitors of OCT1 were identified. Three of the 
substrates –methylnaltrexone, meptazinol, and hydromorphone– are active compounds used 
in clinical practice. Uptake of methylnaltrexone into OCT1-overexpressing cells was 32 to 
85 times higher than that into negative control cells, making it one of the substances most 
dependent on OCT1-mediated transport so far reported. Inhibitors were defined as 
substances with IC50 values of 100 µM or below; of the fourteen inhibitors identified, nine 
were especially potent with IC50 values of less than 25 µM. Notably, dextromethorphan and 
its metabolites were among the substances with the lowest IC50 values. Three of the inhibitors 
–namely dextromethorphan, levorphanol, and tapentadol– could, theoretically, reach portal 
vein concentrations high enough to inhibit OCT1 in vivo.  
70 
 
We also identified five opioids –codeine, hydrocodone, naltrexone, oxycodone, and 
oxymorphone– that can be considered pharmacokinetically “safe” with respect to variations 
in SLC22A1 since they do not seem to interact with OCT1 in any way. Their uptake into 
OCT1-overexpressing cells was less than two times the uptake into negative control cells, 
indicating a lack of OCT1-mediated transport. They also failed to inhibit the uptake of ASP+ 
into OCT1-overexpressing cells by 50 % at concentrations of 100 µM.  
Analysis of the in silicio data showed that opioids with low logD(7.4) and Pe values are more 
likely to be morphinans, and substrates or non-inhibitors of OCT1 than opioids with high 
logD(7.4) and Pe values. It also appears that the structures of synthetic opioids and 
dextromethorphan-like opioids lend themselves to more potent inhibition of OCT1 than the 
“classic” morphinan structure of morphine and its congeners. 
Overall, this study identified at least three substrates and three inhibitors that warrant further 
research in humans in order to gauge their pharmacological and pharmacokinetic impact on 
patients with diminished OCT1 transport activity. In addition, our in vitro data suggests five 





6.1 An overview of the tested drugs 
6.1.1 3-Hydroxymorphinan  
Colloquially, 3-hydroxymorphinan refers to (+)-3-hydroxymorphinan; its levo isomer, (―)-
3-hydroxymorphinan, is better known as norlevorphanol. While lacking intrinsic activity with 
regard to opioid receptors, (+)-3-hydroxymorphinan has emerged as a potent 
neuroprotective agent in animal models and may be of use in the therapy of Parkinson’s 
disease (Zhang et al. 2005). Ultimately a metabolite of dextromethorphan, (+)-3-
hydroxymorphinan is metabolized from dextrorphan via CYP3A4 or from 3-
methoxymorphinan via CYP2D6 (Vengurlekar et al. 2002). 
6.1.2 3-Methoxymorphinan 
A metabolite of dextromethorphan, 3-methoxymorphinan is generated via CYP3A4 
mediated N-demethylation in the liver (Vengurlekar et al. 2002) .It is currently thought to be 
inactive, though further processing by CYP2D6 yields 3-hydroxymorphinan. 
6.1.3 Codeine 
Codeine is a prodrug and precursor of the opioid morphine. It is considered a weak opioid 
that unfolds its analgesic effects after CYP2D6-mediated O-demethylation of the phenylic 
hydroxyl group transforms it into morphine (Hardy and Jackson 2009). Codeine is 
administered as an antitussive and as an antidiarrheal agent. Although codeine is part of many 
antitussive preparations, it is probably no more effective than a placebo at battling coughs 
(Smith et al. 2014). Loperamide –another opioid commonly employed against diarrhea- 
causes fewer side effects, but codeine is cheaper and therefore more likely to be used in 
countries where access to superior –and more expensive- opioids is limited (Hardy and 
Jackson 2009; International Narcotics Control Board  2011)  
6.1.4 Dextromethorphan 
Dextromethorphan is the prodrug of dextrorphan; all its metabolites are dextrorotatory. 
Though displaying only weak affinity for opioid receptors, it acts agonistically on the sigma 
1 receptor and inhibits the uptake of norepinephrine and serotonin (Pioro 2014). In 2010, 
the FDA approved of a formulation of dextromethorphan in combination with quinidine –
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a CYP2D6 inhibitor that delays metabolization of dextromethorphan- for the treatment of 
pseudobulbar affect (Pioro 2014). Additionally, dextromethorphan may act as a weak 
serotonin reuptake inhibitor, though supra-therapeutic doses (as may be encountered in 
abuse) are required in combination with MAOIs to produce serotonin toxicity (Gillman 
2005; Schwartz et al. 2008; Koren-Michowitz et al. 2014). In a study by Reissig, 11 of out 12 
participants rated dextromethorphan as a classic hallucinogenic after receiving doses of 
400mg/70kg BM (Reissig et al. 2012). Because of its antitussive properties, 
dextromethorphan is a common ingredient in many over-the-counter cough medicines in a 
range that spans 5-30mg DXM HBr per formula. Cheap and easily accessible when compared 
to other drugs, recreational abuse of dextromethorphan (called “robo-tripping”, after cough 
medicine-producing brand Robitussin) is no rarity (Wikipedia 2018a). The FDA issued a 
warning against DXM abuse in 2005 after five teenagers died from consuming pure, 
powdered dextromethorphan (FDA 2005). DXM abuse has been in decline ever since, 
though the prevalence of cough medicine abuse among 12th graders still amounts to 4%, one 
in twenty-five students (NIDA 2015). 
6.1.5 Dextrorphan 
Dextrorphan is a metabolite of dextromethorphan derived from CYP2D6-mediated O-
demethylation of the hydroxyl group at the phenolic C3 (Vengurlekar et al. 2002). The 
dextro-rotatory enantiomer of levorphanol, dextrorphan is not, strictly speaking, an opioid 
as it does not bind to opioid receptors. It does bind to N-methyl-D-aspartate (NMDA) 
receptors at the phencyclidine site, though, making it a NMDA receptor antagonist (Davis 
2009d). Competitive binding assays in rat forebrain showed that the IC50 of dextrorphan lay 
below that of ketamine, levorphanol, and dextromethorphan (Franklin and Murray 1992). 
Dextrorphan can be converted into 3-hydroxymorphinan through CYP3A4-mediated N-
demethylation (Vengurlekar et al. 2002). 
6.1.6 Fentanyl 
Fentanyl is a 4-anilidopipderidine derivative and a highly lipophilic compound, with an 
analgesic potency estimated to be nearly 100 times that of morphine. Due to its high lipid 
solubility, it can pass the brain-blood barrier and even the skin, allowing for fentanyl 
formulations that are unique among the opioids. These include TTS (transdermal therapeutic 
systems- “patches”), buccal tablets, sublingual and nasal sprays, and the “lozenge”, which is 
basically a fentanyl-containing lollipop (Mandel and Carunchio 2011; Bornemann-Cimenti et 
al. 2013). These rapid-onset preparations of fentanyl are popular in the treatment of 
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breakthrough cancer pain: the application is non-invasive and bypasses the liver, so that 
ultimately a higher amount of active fentanyl reaches the brain (Bornemann-Cimenti et al. 
2013). About 50 to 75% of orally ingested fentanyl undergoes first-pass metabolism to 
norfentanly, which is then excreted by the kidneys (Bornemann-Cimenti et al. 2013). Though 
short-acting in single doses, fentanyl can accumulate within the cells and adipose tissue if 
given repeatedly. When given continuously, it no longer qualifies as a short-acting opioid 
(Brayfield 2014). 
Fentanyl is currently the most commonly applied opioid worldwide (International Narcotics 
Control Board  2011).  
6.1.7 Hydrocodone 
Hydrocodone is a semi-synthetic derivative of codeine with approximately the same analgesic 
potency as morphine. It is, however, considered a weak opioid as it is only commercially 
available as a compound analgesic, usually with ibuprofen or acetaminophen (Davis 2009a). 
CYP2D6-mediated O-demethylation of hydrocodone yields the more potent 
hydromorphone (analogously to codeine and morphine), while CYP3A4-mediated 
transformation and reduction yield small quantities of norhydrocodone and 6β-/6α-1-
hydromorphol, which also activate MOP (Davis 2009a). Ultra-rapid metabolizers of 
CYP2D6 are reported to be at greater risk of suffering from adverse reactions against 
hydrocodone, probably a result of overdosing since greater amounts of the potent 
hydromorphone will be produced within a shorter time. 
6.1.8 Hydromorphone 
A metabolite of hydrocodone, hydromorphone is a potent congener of morphine used in 
moderate to severe pain. It has been used for the treatment of cancer pain since 1932 
(Quigley and Glare 2009). Analogously to morphine, hydromorphone is glucuronidated to 
hydromorphone-3-glucuronide and excreted via the kidneys, and like morphine-3-
glucuronide, HM3G is suspected of being neurotoxic (Quigley and Glare 2009). 
6.1.9 Levorphanol 
Levorphanol (levo-3-hydroxy-N-methylmorphinan) is the levo-rotatory enantiomer of 
dextrorphan (Davis 2009d). Its analgesic potency is four to eight times that of morphine, and 
it has an especially high affinity for KOP (Prommer 2007). Like dextromethorphan and its 
metabolites, levorphanol acts antagonistically upon NMDA receptors. It has also been noted 
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for causing spasm of the sphincter of Oddi and for stimulating the hypothalamic-pituitary 
axis (Davis 2009d). Analogously to morphine and related compounds, levorphanol is mainly 
metabolized to levorphanol-3-glucuronide (L3G). L3G is thought to be inactive and 
undergoes enterohepatic circulation in mice (Davis 2009d). Ultimately, all metabolites are 
excreted via the kidneys, and only small amounts of levorphanol are excreted unchanged 
(Prommer 2007). 
6.1.10 Meptazinol 
Meptazinol is a synthetic opioid developed in the early nineteen-eighties with an analgesic 
potency ten times lower than that of morphine. A mixed opioid agonist-antagonist, it may 
precipitate withdrawal symptoms in opioid-dependent patients and seems to have cholinergic 
effects, too (Holmes and Ward 1985; Brayfield 2014). Though Meptazinol can cross the 
placenta –which may occur when the drug is administered as an analgesic to women in 
labor― it is quickly eliminated from the neonate (Franklin et al. 1981). Only 10% of 
meptazinol is excreted unchanged via the kidneys, the rest is metabolized by the liver, mainly 
via glucuronidation (Franklin et al. 1975). 
6.1.11 Methylnaltrexone 
Methylnaltrexone is a selective MOP antagonist administered as an adjuvant to palliative care 
patients suffering from opioid-induced constipation (Rodrigues et al. 2013; Brayfield 2014). 
Due to a quaternary nitrogen atom, it is polar and does not cross the brain-blood barrier 
(Leppert 2015). Methylnaltrexone undergoes sulfation to methylnaltrexone-3-sulfate and 
reduction to different methylnaltrexols, though apparently no demethylation to naltrexone 
(Leppert 2015). Approximately 40% are excreted unchanged by the kidneys; another 20% 
with the feces (Leppert 2015). 
6.1.12 Morphine 
Morphine is an opiate and the prototypic opioid. Analgesic potency is scaled with reference 
to morphine (analgesic potency of 1) and, along with codeine, it is one of two opioids 
declared essential drugs by the WHO (Glare 2009a; WHO 2015). Despite the wide offer of 
alternative opioids, morphine remains the most popular opioid in pediatrics and is the opioid 
of choice in the treatment of cancer pain (Brayfield 2014). Its main metabolites, morphine-
3-glucuronide and morphine-6-glucuronide, are formed via UDP-glucuronosyltransferase 
(UGT). Morphine and all of its metabolites are excreted by the kidneys, which is why 
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morphine should be administered with caution in patients with decreased renal 
clearance(Glare 2009a). Like codeine and pethidine, morphine is known to trigger the release 
of histamine from mast cells, resulting in erythrema and itching (Blunk et al. 2004). It can 
also cause spasms of the sphincter of Oddi (Helm et al. 1988). 
6.1.13 Naltrexone 
In contrast to methylnaltrexone, naltrexone is an opioid receptor antagonist that is active 
peripherally as well as centrally (Barnett et al. 2014). Naltrexone undergoes first-pass 
metabolism in the liver to 6-β-naltrexol, which, too, has antagonist properties (Barnett et al. 
2014). It is employed in the long-term treatment of cholestatic pruritus, but may counteract 
the analgesic effects of co-administered opioids and cause typical withdrawal symptoms 
(Barnett et al. 2014). Administered as an adjunct in the management of alcohol dependence, 
naltrexone reduces the amounts of alcohol ingested (Volpicelli et al. 1992; Brayfield 2014). 
It is further under investigation as a therapeutic drug in eating disorders, and may be 
beneficial in autistic children with self-injurious behavior (Brayfield 2014). 
6.1.14 N-Desmethyltramadol 
N-Desmethyltramadol (M2) is a CYP3A4 and CYP2B6-derived metabolite of tramadol 
(Leppert 2011). Its effects are unknown.  
6.1.15 Norfentanyl 
Norfentanyl is produced by CYP3A4-mediated N-demethylation of fentanyl (Hall and Hardy 
2009). It is considered an inactive metabolite. 
6.1.16 Noroxycodone 
Noroxycodone is a weak opioid receptor agonist derived from oxycodone through CYP3A4-
mediated N-demethylation (Smith 2011). Its impact on analgesia, however, is negligible. 
CYP2D6-mediated O-demethylation of noroxycodone can yield noroxymorphone, but most 
of it will be excreted by the kidneys unchanged (Glare and Davis 2009; Smith 2011).  
6.1.17 Nortilidine 
Nortilidine is the active metabolite of tilidine, produced by CYP3A4-mediated N-
demethylation in the liver (Grun et al. 2012). With an opioid receptor affinity ten times that 
of the parent drug, nortilidine is about equianalgesic to morphine (Hajda et al. 2002). Apart 
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from being an opioid receptor agonist, nortilidine is also an NMDA receptor antagonist and 
dopamine reuptake inhibitor (Brayfield 2014). 
6.1.18 Oxycodone 
Oxycodone is a thebaine congener with approximately the same analgesic potency as 
morphine (Glare and Davis 2009). Due to its extensive and varied metabolization, 
oxycodone is sometimes regarded as a prodrug, exerting its analgesic effects through 
oxymorphone and noroxymorphone (Smith 2011). CYP2D6-mediated O-demethylation of 
oxycodone yields oxymorphone; however, CPY3A4-mediated N-demethylation to 
noroxycodone dominates in vivo (Smith 2011). Along with fentanyl, hydromorphone, and 
morphine, oxycodone is one of the most commonly applied opioids worldwide 
(International Narcotics Control Board  2011). Its popularity may be partly grounded in the 
fact that is has been in use since 1917, and decades of clinical experience have made a wide 
array of formulations, among them sustained-release tablets, available  
6.1.19 Oxymorphone 
Oxymorphone is a semi-synthetic opioid congener and a metabolite of oxycodone. It is more 
than six times as potent as morphine, and immediate-release and extended-release tablets 
made available in 2006 paved the way for more wide-spread use of oxymorphone in the 
management of cancer pain (Glare 2009b). Oxymorphone has an oral availability of 10%, 
and analogously to morphine, it is metabolized to and excreted as oxymorphone-3-
glucuronide, though small amounts of alpha- and beta-6-oxymorphol are produced (Glare 
2009b; Smith 2011). 
6.1.20 Pethidine (Meperidine) 
Pethidine (synonym: meperidine) is a synthetic opioid and a peperidine, like fentanyl, and 
equally lipophilic (Davis 2009c). It has been in clinical use since 1939 (Corbett et al. 2006). 
Its major metabolite, meperidinic acid, is produced by hydrolysis and then glucuronidated 
before excretion, while another metabolite, normeperidine, is synthesized through CYP3A4-
mediated N-demethylation (Smith 2011). Liver and kidney disease lead to an accumulation 
of these metabolites and a build-up of, a neurotoxic agent known to cause tremors, 
myoclonus and seizures (Szeto et al. 1977; Kaiko et al. 1983). Adverse side effects were also 
more common in patient-controlled analgesia (Brayfield 2014). In 2011, the FDA expanded 
the list of contraindications, highlighting the increased awareness of pethidine side effects 
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(FDA 2011). Additionally, pethidine is a weak serotonin reuptake inhibitor, and in 
combinations with monoamino oxidase (MAO) inhibitors it has been reported to cause fatal 
serotonin toxicity (Gillman 2005). Although the use of pethidine is currently being 
discouraged -more so as alternative opioids with less pronounced side effects are available- 
it is still among the seven most commonly administered opioids worldwide(Latta et al. 2002; 
Davis 2009c; International Narcotics Control Board  2011). It is widely used in obstreterix 
(Brayfield 2014). 
6.1.21 Sufentanil 
Sufentanil is a highly lipophilic congener of fentanyl and about 500 times as potent as 
morphine, making it the most potent opioids administered to humans (Hall and Hardy 2009). 
Because of its rapid inset and recovery, sufentanil is used as an adjunct in anesthesia, 
postoperative pain, and labor pain, and, like fentanyl, it may accumulate when given 
repeatedly, especially in obese patients. About 2% are eliminated unchanged via the kidneys, 
the rest undergoes N-dealkylation and O-demethylation in the liver and small (Hall and 
Hardy 2009). 
6.1.22 Tapentadol 
Tapentadol is a relatively new opioid that was approved for use by the FDA in 2008 (Singh 
et al. 2013). It is nearly completely metabolized to tapentadol-O-glucuronide and other minor 
metabolites, such as N-desmethyltapentadol (Singh et al. 2013). Apart from acting upon 
opioid receptors, tapentadol inhibits noradrenaline reuptake (Tzschentke et al. 2011). The 
higher concentrations of noradrenaline contribute to the overall analgesic effect, so that 
tapentadol, despite a 44-lower binding affinity to MOP than morphine, has an analgesic 
potency of 0.4 (Tzschentke et al. 2011). 
6.1.23 Tilidine 
Tilidine is a synthetic opioid and prodrug of the active compound nortilidine. Classified as 
weak opioid, it is employed as analgesic in moderate acute and chronic pain. CYP3A4 and 
CYP 2C19-mediated demethylation yield nortilidine and bisnortilidine (Grun et al. 2012). It 
is available as single formulation or in combination with naloxone, an opioid receptor 
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